S.no |
Heading Name |
Date |
Edit |
Delete |
1 |
Institutional Review Board (IRB) |
2024-11-21 |
|
|
2 |
Ethical Committe |
2024-11-21 |
|
|
3 |
Conflicts Of Intrest |
2024-10-23 |
|
|
4 |
CONFLICTS OF INTEREST |
2024-10-23 |
|
|
5 |
Data Sharing |
2024-10-22 |
|
|
6 |
Authors Declaration of Approval |
2024-10-22 |
|
|
7 |
Criteria for Inclusion in the Authors’ List |
2024-10-22 |
|
|
8 |
Previous Presentation of the Study |
2024-10-22 |
|
|
9 |
Initial Therapy |
2024-10-09 |
|
|
10 |
Limitations of the research |
2024-09-27 |
|
|
11 |
Anti-cancer Activity |
2024-09-05 |
|
|
12 |
Hyperlipidimic Activity |
2024-09-05 |
|
|
13 |
Anti-protozoal Activity |
2024-09-05 |
|
|
14 |
Anti-oxidant Activity |
2024-09-05 |
|
|
15 |
Anti-inflammatory Activity |
2024-09-05 |
|
|
16 |
Anti-helmnthic Activity |
2024-09-05 |
|
|
17 |
Anti-diabetic Activity |
2024-09-05 |
|
|
18 |
Artemisia roxburghiana |
2024-09-05 |
|
|
19 |
The Answers of the New Model, to the Questions Left Unanswered by the Standard Model |
2024-08-30 |
|
|
20 |
The New Model for the Subatomic Particles and the Fundamental Interactions |
2024-08-30 |
|
|
21 |
The Questions Set In Doubt the Standard Model Theory |
2024-08-30 |
|
|
22 |
The Standard Model |
2024-08-30 |
|
|
23 |
Settings of the Problem |
2024-07-11 |
|
|
24 |
Discrete Kalman Filter Algorithm |
2024-07-11 |
|
|
25 |
State Estimation and Nonlinear Filtering |
2024-07-11 |
|
|
26 |
Kalman Filter |
2024-07-11 |
|
|
27 |
Data Available |
2024-07-04 |
|
|
28 |
APPENDIX 4 |
2024-07-02 |
|
|
29 |
APPENDIX 3 |
2024-07-02 |
|
|
30 |
APPENDIX 2 |
2024-07-02 |
|
|
31 |
APPENDIX 1 – Problem Session |
2024-07-02 |
|
|
32 |
Chapter 8 Introduction to Self-Generating Primal Groups & Peano ´S Postulates to Generate the Prime Numbers |
2024-07-02 |
|
|
33 |
Chapter 7 Rules for Tables and Creating Tables |
2024-07-02 |
|
|
34 |
Chapter 6 Building Rppn Tables |
2024-07-02 |
|
|
35 |
Chapter 5 Physical Dimensions Of Sppn Tables |
2024-07-02 |
|
|
36 |
Chapter 4 Converting between Mod10 and Modnt Number Systems |
2024-07-02 |
|
|
37 |
Chapter 3 Notes on MODnt number system |
2024-07-02 |
|
|
38 |
Chapter 2 Creating sppn tables |
2024-07-02 |
|
|
39 |
Chapter 1 What the ancient greeks knew and what they did not know and what every mathematician since has failed to realize |
2024-07-02 |
|
|
40 |
Analysis of the Development Status of Mass Sports |
2024-07-01 |
|
|
41 |
Analysis of the Development Status of Mass Sports |
2024-07-01 |
|
|
42 |
Overview of Behavioral Economics Theory |
2024-07-01 |
|
|
43 |
The Explicit Formula for Stirling Numbers of the second kind |
2024-06-20 |
|
|
44 |
Relation between Bernoulli Numbers and Stirling Numbers of the Second Kind |
2024-06-11 |
|
|
45 |
Stirling Numbers of the Second Kind |
2024-06-11 |
|
|
46 |
Annexes |
2024-06-03 |
|
|
47 |
Main Property of the Surjection |
2024-06-03 |
|
|
48 |
The "Theory of the Chain Reaction" and the "New Model" for The Subatomic Particles and Fundamental Interactions (A New Attempt to Explain the Creation of the Cosmos) |
2024-05-07 |
|
|
49 |
Recapitulation of the Established Views of Science on the Creation and the Functioning of the Universe |
2024-05-06 |
|
|
50 |
The General Theory of Relativity and the Explanation of the Interaction of Gravity |
2024-05-06 |
|
|
51 |
The Completion of the Big Bang Theory by the Standard Model Theory |
2024-05-06 |
|
|
52 |
The New Age and the Big Bang Theory |
2024-05-06 |
|
|
53 |
The Renaissance and the Heliocentric System |
2024-05-06 |
|
|
54 |
The Middle Ages |
2024-05-06 |
|
|
55 |
The First Scientific Explanations and the Geocentric System |
2024-05-06 |
|
|
56 |
The Knowledge of the Primitive Man, The Mythology and the Religions |
2024-05-06 |
|
|
57 |
Conclusion by Scientific Hypothesis |
2024-05-02 |
|
|
58 |
Homogeneous Riemannian Manifolds with Applications to Primes |
2024-05-02 |
|
|
59 |
Preliminaries |
2024-04-29 |
|
|
60 |
Source |
2024-04-05 |
|
|
61 |
Time in UPL Model |
2024-03-01 |
|
|
62 |
Black Holes with Schwarzschild Radius |
2024-03-01 |
|
|
63 |
Distortion in Space Caused by Antiuholes |
2024-03-01 |
|
|
64 |
Model UPL Related To General Relativity |
2024-03-01 |
|
|
65 |
Multiple Representations of The UPL Model |
2024-03-01 |
|
|
66 |
Calculations of Pressures And Forces On The UPL Model |
2024-03-01 |
|
|
67 |
Gravitational Forces On The UPL Model |
2024-03-01 |
|
|
68 |
UPL Model |
2024-03-01 |
|
|
69 |
Mass Annihilation |
2024-03-01 |
|
|
70 |
Negative Mass |
2024-03-01 |
|
|
71 |
CASE DETAILS ATTACHED |
2024-03-01 |
|
|
72 |
Sensitivity Analysis |
2024-02-05 |
|
|
73 |
OC problem for S-I-R Model |
2024-02-05 |
|
|
74 |
Description of the Sir Epidemic Model |
2024-02-05 |
|
|
75 |
Related Studies |
2024-02-05 |
|
|
76 |
Competing Interests Statement |
2024-01-04 |
|
|
77 |
Availability of Data |
2024-01-03 |
|
|
78 |
Publication Consent |
2023-11-20 |
|
|
79 |
Funding and Conflict of Interest |
2023-11-09 |
|
|
80 |
Author-Contributions |
2023-11-08 |
|
|
81 |
Physiotherapy Management |
2023-10-13 |
|
|
82 |
Stages of Fasciotomy |
2023-10-13 |
|
|
83 |
Layers of Skin |
2023-10-13 |
|
|
84 |
Current Trends in Compartment Syndrome |
2023-10-13 |
|
|
85 |
Compartment Syndrome |
2023-10-13 |
|
|
86 |
Future Research Recommendations |
2023-10-10 |
|
|
87 |
Using ICAR |
2023-10-04 |
|
|
88 |
Building ICAR |
2023-10-04 |
|
|
89 |
Retail Spc Data Space Ad Its Transformation |
2023-09-29 |
|
|
90 |
Formulation Of Retailing Elements |
2023-09-29 |
|
|
91 |
Energy balance |
2023-09-23 |
|
|
92 |
Annex a1 |
2023-09-20 |
|
|
93 |
Part 2 |
2023-09-11 |
|
|
94 |
Part 1 |
2023-09-11 |
|
|
95 |
Data Sharing Statement |
2023-09-02 |
|
|
96 |
Life Science Reporting |
2023-08-28 |
|
|
97 |
Grant Support Details |
2023-08-28 |
|
|
98 |
Calculation of g |
2023-08-09 |
|
|
99 |
Equation for g |
2023-08-09 |
|
|
100 |
Presentation at a Meeting |
2023-08-08 |
|
|
101 |
Strength |
2023-08-05 |
|
|
102 |
A value for α |
2023-08-04 |
|
|
103 |
Application to the photon gas |
2023-08-04 |
|
|
104 |
The hamiltonian operator |
2023-08-04 |
|
|
105 |
Complex Numbers of Riemann Hypothesis |
2023-07-31 |
|
|
106 |
Introduction(Section 1) |
2023-07-31 |
|
|
107 |
References (Section 12) |
2023-07-26 |
|
|
108 |
Software Availability (Section 11) |
2023-07-26 |
|
|
109 |
Acknowledgements (Section 10) |
2023-07-26 |
|
|
110 |
Abbreviations (Section 9) |
2023-07-26 |
|
|
111 |
Appendix (8) |
2023-07-26 |
|
|
112 |
Conclusion (Section 7) |
2023-07-26 |
|
|
113 |
Potential benefits of a new Mathematics as an Amalgamation of IC as a Foundation for Intelligence and IC as a Foundation for Mathematics (Section 7) |
2023-07-26 |
|
|
114 |
Potential benefits of a new Mathematics as an Amalgamation of â??IC as a Foundation for Intelligenceâ?? and â??IC as a Foundation for Mathematicsâ?? (Section 7) |
2023-07-26 |
|
|
115 |
Potential benefits of a new Mathematics as an Amalgamation of â??IC as a Foundation for Intelligenceâ?? and â??IC as a Foundation for Mathematicsâ?? (Section 7) |
2023-07-26 |
|
|
116 |
Potential benefits of a new Mathematics as an Amalgamation of &Lsquo;Ic as a Foundation for Intelligence&Rsquo; and &Lsquo;Ic as a Foundation for Mathematics&Rsquo; (Section 7) |
2023-07-26 |
|
|
117 |
How six other variants of ICMUP may be modelled via the SPMA concept (Section 6) |
2023-07-26 |
|
|
118 |
The SPMA Concept as a Variant of ICMUP (Section 5) |
2023-07-26 |
|
|
119 |
IC Via ICMUP (Section 4) |
2023-07-26 |
|
|
120 |
The SP-Multiple-Alignment Concept (Section 3) |
2023-07-26 |
|
|
121 |
A Bare-Bones Introduction to the SPTI (Section 2) |
2023-07-26 |
|
|
122 |
Challenges and future directions |
2023-07-11 |
|
|
123 |
Data sharing agreement |
2023-07-11 |
|
|
124 |
Acknowlegement |
2023-07-06 |
|
|
125 |
Theorem |
2023-07-06 |
|
|
126 |
The Barycenter |
2023-07-06 |
|
|
127 |
Experimental Steps |
2023-07-03 |
|
|
128 |
Light: Particle or Wave? |
2023-06-27 |
|
|
129 |
The Energy Force |
2023-06-27 |
|
|
130 |
Trap sim ii |
2023-06-26 |
|
|
131 |
Stroboscopic exponentiation algorithm |
2023-06-26 |
|
|
132 |
Classical quantum-simulation algorithms |
2023-06-26 |
|
|
133 |
Cryptographical Properties of the Sequence |
2023-06-26 |
|
|
134 |
Description of Pseudo Random Bit Generator using DLFSR |
2023-06-26 |
|
|
135 |
Technical Preliminaries |
2023-06-26 |
|
|
136 |
Model Description |
2023-06-23 |
|
|
137 |
Lamp Description |
2023-06-23 |
|
|
138 |
Data Collection And Outcomes |
2023-06-20 |
|
|
139 |
Eligibility Criteria |
2023-06-20 |
|
|
140 |
Study design and Participants |
2023-06-20 |
|
|
141 |
Bell’s theorem |
2023-06-20 |
|
|
142 |
Bellâ??s theorem |
2023-06-20 |
|
|
143 |
The bell experiment |
2023-06-20 |
|
|
144 |
Ion trap quantum computers |
2023-06-20 |
|
|
145 |
Application |
2023-06-16 |
|
|
146 |
Main result |
2023-06-16 |
|
|
147 |
INTERPRETATION OF SCORES |
2023-06-15 |
|
|
148 |
DEVICE DESCRIPTION |
2023-06-15 |
|
|
149 |
Explanation of Test Results II |
2023-06-12 |
|
|
150 |
Explanation of Test Results I |
2023-06-12 |
|
|
151 |
Data Normalization |
2023-06-12 |
|
|
152 |
Data and Variables |
2023-06-12 |
|
|
153 |
Identity Disorder |
2023-06-08 |
|
|
154 |
Numerical Example |
2023-06-05 |
|
|
155 |
Design Method of Minimum-Phase Stabilizing Controllers |
2023-06-05 |
|
|
156 |
Properties of the Control System |
2023-06-05 |
|
|
157 |
The Parameterization of all Stabilizing Minimum-Phase Controllers for Minimum-Phase Strictly Proper Plants |
2023-06-05 |
|
|
158 |
Discussion & finding of study |
2023-06-01 |
|
|
159 |
Research questions |
2023-06-01 |
|
|
160 |
Acknowledgement/Funding |
2023-05-30 |
|
|
161 |
Contribution to Knowledge |
2023-05-30 |
|
|
162 |
Study objectives |
2023-05-12 |
|
|
163 |
Conclusion and Scope for Future Work |
2023-04-27 |
|
|
164 |
Comparison |
2023-04-27 |
|
|
165 |
Hyperparameters |
2023-04-27 |
|
|
166 |
Different Techniques Used |
2023-04-27 |
|
|
167 |
Data Preparation |
2023-04-27 |
|
|
168 |
List of Features Used in Modelling |
2023-04-27 |
|
|
169 |
Notations |
2023-04-27 |
|
|
170 |
Related Research |
2023-04-27 |
|
|
171 |
Author Declaration |
2023-04-26 |
|
|
172 |
Interpretation |
2023-04-26 |
|
|
173 |
Results Summary and Analysis |
2023-04-24 |
|
|
174 |
Research |
2023-04-24 |
|
|
175 |
Creating a Digital Game-Based Learning Game Focused on Arithmetic Training |
2023-04-24 |
|
|
176 |
CASE NO. 2 |
2023-04-12 |
|
|
177 |
CASE NO. 1 |
2023-04-12 |
|
|
178 |
The Clinical Outcomes |
2023-04-05 |
|
|
179 |
Termination Of Injection |
2023-04-05 |
|
|
180 |
Cement Mixing & Injection |
2023-04-05 |
|
|
181 |
Transpedicular Approach |
2023-04-05 |
|
|
182 |
Postoperative Evaluation |
2023-04-05 |
|
|
183 |
Numerical Simulations |
2023-04-05 |
|
|
184 |
Sensitivity Analysis of R0 |
2023-04-05 |
|
|
185 |
Stability Analysis |
2023-04-05 |
|
|
186 |
Model Formulation and Description |
2023-04-05 |
|
|
187 |
Choosing the Right Reference Frame |
2023-03-28 |
|
|
188 |
Molecular Dynamics Simulation Analysis Of Pd1 And One Of Its Hit Compounds |
2023-03-24 |
|
|
189 |
Mandible-First Approach And Maxilla-First Approach |
2023-03-23 |
|
|
190 |
Single-Splint Technique And Double-Splint Technique |
2023-03-23 |
|
|
191 |
Surgical Planning |
2023-03-23 |
|
|
192 |
Orthodontic Treatment |
2023-03-23 |
|
|
193 |
Clinical Studies |
2023-03-23 |
|
|
194 |
Socket Shield Technique |
2023-03-23 |
|
|
195 |
Treatment And Prognosis |
2023-03-23 |
|
|
196 |
Histopathological Features |
2023-03-23 |
|
|
197 |
Clinical And Radiographic Features |
2023-03-23 |
|
|
198 |
Smokeless (Chewing) Tobacco |
2023-03-23 |
|
|
199 |
Smoked Tobacco |
2023-03-23 |
|
|
200 |
Surface Treatments |
2023-03-23 |
|
|
201 |
Polymerisation Cycle |
2023-03-23 |
|
|
202 |
Mixing Ratios |
2023-03-23 |
|
|
203 |
Solubility Of Base Material By-products |
2023-03-23 |
|
|
204 |
Methods and Results |
2023-03-22 |
|
|
205 |
The Thermodynamical Relation |
2023-03-13 |
|
|
206 |
Solution of Field Equations |
2023-03-13 |
|
|
207 |
The Metric and Basic Equations |
2023-03-13 |
|
|
208 |
Sources of Support |
2023-03-08 |
|
|
209 |
Adrenal Insufficiency |
2023-03-04 |
|
|
210 |
Adrenal Gland Hormones |
2023-03-04 |
|
|
211 |
Patient Consent for Publication |
2023-03-01 |
|
|
212 |
Conclusion and Discussion |
2023-02-28 |
|
|
213 |
APPLICATIONS OF HERBAL MEDICINE |
2023-02-27 |
|
|
214 |
HERBAL MEDICINE LOADED NATURAL POLYMER |
2023-02-27 |
|
|
215 |
SYNTHESIS OF POLYMER LOADED WITH HERBAL MEDICINE |
2023-02-27 |
|
|
216 |
METHODS FOR ASSESSING NUTRITIONAL STATUS IN CANCER CHILDREN |
2023-02-25 |
|
|
217 |
BIOMATERIALS COMBINED WITH REGENERATIVE MEDICINE |
2023-02-25 |
|
|
218 |
Objectives and methods |
2023-02-23 |
|
|
219 |
Implication Of Study |
2023-02-23 |
|
|
220 |
Study Duration |
2023-02-23 |
|
|
221 |
Sample Size |
2023-02-23 |
|
|
222 |
PROPOSED NEXT STEPS |
2023-02-22 |
|
|
223 |
EVALUATION OF THE STUDY |
2023-02-22 |
|
|
224 |
CLINICAL EVIDENCE SUMMARY OF STUDY |
2023-02-22 |
|
|
225 |
Conflicts Of Interest Statement |
2023-02-22 |
|
|
226 |
Nomenclature |
2023-02-15 |
|
|
227 |
CJG in the Pm Knowledge Space |
2023-02-15 |
|
|
228 |
Pmg and Its Knowledge Analysis |
2023-02-15 |
|
|
229 |
Clinical Message |
2023-02-13 |
|
|
230 |
Consent of Participate |
2023-02-13 |
|
|
231 |
Keypoints |
2023-02-13 |
|
|
232 |
Acknowledgment And Funding |
2023-02-09 |
|
|
233 |
Stages Of Non-Hodgkin Lymphomas |
2023-02-07 |
|
|
234 |
Diagnosis And Tests |
2023-02-07 |
|
|
235 |
Characteristics |
2023-02-07 |
|
|
236 |
Other White Blood Cells: Monocytes And Lymphocytes |
2023-02-07 |
|
|
237 |
Granulocytes: Neutrophils, Eosinophils And Basophils |
2023-02-07 |
|
|
238 |
Erythrocytes |
2023-02-07 |
|
|
239 |
Bone Marrow And Hematopoiesis |
2023-02-07 |
|
|
240 |
Transfusion Recipient Molecular Typing |
2023-02-07 |
|
|
241 |
Blood Donor Molecular Typing |
2023-02-07 |
|
|
242 |
The Effect of Elimination On Human Being |
2023-02-07 |
|
|
243 |
Malthusian Trap and The Economic Growth |
2023-02-07 |
|
|
244 |
Fundamental Elimination Mechanism |
2023-02-07 |
|
|
245 |
Basic Relation between Resource and Population |
2023-02-07 |
|
|
246 |
Dispersion Polymerization Techniques For The Fabrication of Polymeric Nanoparticles For Biomedical Applications |
2023-02-07 |
|
|
247 |
Fabrication Of Polymeric Nanoparticles |
2023-02-07 |
|
|
248 |
Advantages Of Nanoparticles |
2023-02-07 |
|
|
249 |
Classifications |
2023-02-06 |
|
|
250 |
Classifications |
2023-02-06 |
|
|
251 |
CELLULOSE - CHITOSAN FUNCTIONAL BIOCOMPOSITES |
2023-02-06 |
|
|
252 |
CELLULOSEâ??CHITOSAN FUNCTIONAL BIOCOMPOSITES |
2023-02-06 |
|
|
253 |
Abbreviation: |
2023-02-03 |
|
|
254 |
Evaluation phase |
2023-02-03 |
|
|
255 |
Material Methods |
2023-02-03 |
|
|
256 |
Data interpretation |
2023-01-25 |
|
|
257 |
DEPOSITIONAL SETTING |
2023-01-25 |
|
|
258 |
LIGAMENTS INVOLVED & MECHANISM OF INJURY |
2023-01-23 |
|
|
259 |
Data collection and measures |
2023-01-23 |
|
|
260 |
Exclusion criteria were as follows |
2023-01-23 |
|
|
261 |
Findings and discussion |
2023-01-10 |
|
|
262 |
Organic nanoparticles |
2023-01-10 |
|
|
263 |
The Author |
2023-01-10 |
|
|
264 |
Remarks |
2023-01-09 |
|
|
265 |
Effect of nanoparticles on different organs |
2023-01-09 |
|
|
266 |
Routes of human body adsorption of nanoparticles |
2023-01-09 |
|
|
267 |
ORGANIC NANOPARTICLES |
2023-01-09 |
|
|
268 |
Inorganic nanoparticles |
2023-01-09 |
|
|
269 |
Nanoparticles as antibiotic agents |
2023-01-09 |
|
|
270 |
Nanomaterial-induced OS measurement |
2023-01-09 |
|
|
271 |
Oxidative stress |
2023-01-09 |
|
|
272 |
Developing sustainable antimicrobials |
2023-01-09 |
|
|
273 |
Role of Genome |
2023-01-09 |
|
|
274 |
Role of evolution |
2023-01-09 |
|
|
275 |
Evolutionary adaptation and physiological acclimatisation |
2023-01-09 |
|
|
276 |
HISTOPATHOLOGY FINDING |
2023-01-06 |
|
|
277 |
Proof of Theorem |
2023-01-05 |
|
|
278 |
Wheat |
2023-01-03 |
|
|
279 |
SOLUTIONS TO AVOID THE CONS |
2022-12-22 |
|
|
280 |
CONS |
2022-12-22 |
|
|
281 |
WHY IS SOURDOUGH BETTER THAN OTHER BREAD? |
2022-12-22 |
|
|
282 |
SCIENCE BEHIND SOURDOUGH |
2022-12-22 |
|
|
283 |
METABOLISM |
2022-12-22 |
|
|
284 |
HORMONES |
2022-12-22 |
|
|
285 |
Methodology and Research Questions |
2022-12-19 |
|
|
286 |
Literature on the Public Perceptions of Nanotechnology |
2022-12-19 |
|
|
287 |
CONCLUDING NOTES AND FUTURE PROSPECTS |
2022-12-19 |
|
|
288 |
CYCLODEXTRIN BASED NANOSPONGES |
2022-12-19 |
|
|
289 |
Measurement of Variables |
2022-12-17 |
|
|
290 |
Statements and Declarations |
2022-12-16 |
|
|
291 |
pesticides |
2022-12-15 |
|
|
292 |
alteration of crops and biotechnology |
2022-12-15 |
|
|
293 |
the origin and scope |
2022-12-15 |
|
|
294 |
control methods |
2022-12-15 |
|
|
295 |
agribusiness |
2022-12-15 |
|
|
296 |
quantification |
2022-12-15 |
|
|
297 |
Prime Number DAC |
2022-12-15 |
|
|
298 |
Polygonal Number DAC |
2022-12-15 |
|
|
299 |
NANOPARTICLE TYPES |
2022-12-14 |
|
|
300 |
NANOTECHNOLOGY IN MEDICINE |
2022-12-14 |
|
|
301 |
BLOOD COAGULATION STUDY |
2022-12-09 |
|
|
302 |
DETECTION OF IN-VITRO INDUCED PLATELET AGGREGATES |
2022-12-09 |
|
|
303 |
PLATELET AGGREGATION TEST (WU AND HOAK, 1974) |
2022-12-09 |
|
|
304 |
HAEMATOLOGICAL ANALYSIS USING AUTOMATED MACHINE |
2022-12-09 |
|
|
305 |
ANIMAL SACRIFICE AND BLOOD SAMPLE COLLECTION |
2022-12-09 |
|
|
306 |
ANIMAL SACRIFICE AND BLOOD SAMPLE COLLECTIONc |
2022-12-09 |
|
|
307 |
ADMINISTRATION OF ASPIRIN (ACETYLSALICYLIC ACID) |
2022-12-09 |
|
|
308 |
EXTRACTION AND ADMINISTRATION OF ALLIUM CEPA |
2022-12-09 |
|
|
309 |
EXPERIMENTAL ANIMALS |
2022-12-09 |
|
|
310 |
PROCUREMENT OF ALLIUM CEPA |
2022-12-09 |
|
|
311 |
STUDY SITE |
2022-12-09 |
|
|
312 |
MATERIALS AND REAGENTS |
2022-12-09 |
|
|
313 |
OBJECTIVES OF THE STUDY |
2022-12-09 |
|
|
314 |
HYPOTHESIS |
2022-12-09 |
|
|
315 |
RATIONLAE OF STUDY |
2022-12-09 |
|
|
316 |
STATEMENT OF PROBLEM |
2022-12-09 |
|
|
317 |
CONCLUSION |
2022-12-08 |
|
|
318 |
Follow up |
2022-12-07 |
|
|
319 |
β-THALASSEMIA |
2022-12-07 |
|
|
320 |
#946;-THALASSEMIA |
2022-12-07 |
|
|
321 |
α- THALASSEMIA |
2022-12-07 |
|
|
322 |
SCREENING MEASURES TO PROTECT THE RECIPIENT |
2022-12-07 |
|
|
323 |
MEASURES TO PROTECT THE DONOR |
2022-12-07 |
|
|
324 |
APPLICATIONS IN VARIOUS FIELDS |
2022-12-06 |
|
|
325 |
SYNTHESIS: TOP-DOWN AND BOTTOM-UP APPROACHES |
2022-12-06 |
|
|
326 |
CLASSIFICATION OF NANOCELLULOSE |
2022-12-06 |
|
|
327 |
STRUCTURE AND PROPERTIES |
2022-12-06 |
|
|
328 |
Conclusion And Policy Recommendations |
2022-12-05 |
|
|
329 |
Estimation Results |
2022-12-05 |
|
|
330 |
Safety And Tolerability |
2022-11-29 |
|
|
331 |
Erosion And Abrasion Related To Tooth Bleaching |
2022-11-29 |
|
|
332 |
OSTEOPATHY TREATMENTS |
2022-11-29 |
|
|
333 |
Factors Related To Surgery |
2022-11-29 |
|
|
334 |
Analysis Method |
2022-11-29 |
|
|
335 |
Applications of nanomedicine |
2022-11-29 |
|
|
336 |
Applications of nanomedicine |
2022-11-29 |
|
|
337 |
Packaging sustainability improvement strategies |
2022-11-29 |
|
|
338 |
Applications of packaging materials |
2022-11-29 |
|
|
339 |
Applications of packaging materials |
2022-11-29 |
|
|
340 |
Types of packaging materials |
2022-11-29 |
|
|
341 |
Overview of new rice - oryza sativa l. |
2022-11-28 |
|
|
342 |
PREOPERATIVE ASSESSMENT |
2022-11-28 |
|
|
343 |
Genomic biomarkers for non-communicable diseases |
2022-11-24 |
|
|
344 |
Insufficiencies of modern medicine |
2022-11-24 |
|
|
345 |
Nanoparticle as a drug delivery agents in the treatment of CVDS |
2022-11-24 |
|
|
346 |
Nanoparticles for the treatment of heart diseases |
2022-11-24 |
|
|
347 |
Nanoparticles for the treatment of Coronary Artery Disease(CAD) |
2022-11-24 |
|
|
348 |
Complications Of Sub-Tenon’s Anesthesia |
2022-11-24 |
|
|
349 |
Advantages Of Sub-Tenon’s Anesthesia |
2022-11-24 |
|
|
350 |
Advantages Of Sub-Tenonâ??s Anesthesia |
2022-11-24 |
|
|
351 |
Sub-Tenon’s Block Technique |
2022-11-24 |
|
|
352 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
353 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
354 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
355 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
356 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
357 |
Advantages Of Sub-Tenonâ??s Anesthesia |
2022-11-24 |
|
|
358 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
359 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
360 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
361 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
362 |
Sub-Tenonâ??s Block Technique |
2022-11-24 |
|
|
363 |
Limitations In Point-Of-Care Tests |
2022-11-24 |
|
|
364 |
Platelet Function Monitoring |
2022-11-24 |
|
|
365 |
Standard-Bedside Coagulation Tests |
2022-11-24 |
|
|
366 |
Coagulation Cascade |
2022-11-24 |
|
|
367 |
Opioids |
2022-11-24 |
|
|
368 |
Local Anesthetic |
2022-11-24 |
|
|
369 |
Trigeminal Neuralgia |
2022-11-23 |
|
|
370 |
NANODRUGS |
2022-11-23 |
|
|
371 |
CURRENT CLINICAL PRACTICE OF USING PROBIOTICS IN AAD |
2022-11-23 |
|
|
372 |
ROLE PROBIOTICS IN PREVENTING ANTIBIOTICASSOCIATED DIARRHEA |
2022-11-23 |
|
|
373 |
ANTIBIOTIC-ASSOCIATED DIARRHEA |
2022-11-23 |
|
|
374 |
HERBAL TREATMENT APPROACHES |
2022-11-23 |
|
|
375 |
A Global snapshot of opportunities to incorporate nanomedicine education content |
2022-11-23 |
|
|
376 |
Coverage of Nanomedicine through pharmacy education |
2022-11-23 |
|
|
377 |
The influence of pre-existing antibodies on LAIV T- cell immunogenicity |
2022-11-22 |
|
|
378 |
Comparision of pre-clinical and clinical studies to find efficacy of LAIV |
2022-11-22 |
|
|
379 |
Comparision of Live Attenuated Influenza Vaccine (LAIV) with inactivated influenza vaccines |
2022-11-22 |
|
|
380 |
Nanodrugs |
2022-11-22 |
|
|
381 |
Modern Nanotechnology |
2022-11-22 |
|
|
382 |
History of Nanotechnology |
2022-11-22 |
|
|
383 |
HISTORY OF NANOTECHNOLOGY |
2022-11-22 |
|
|
384 |
Limitations of THz imaging methods |
2022-11-22 |
|
|
385 |
THz imaging methods |
2022-11-22 |
|
|
386 |
ENVIRONMENTAL HEALTH |
2022-11-18 |
|
|
387 |
Issues with Genome-Enabled EMRs |
2022-11-17 |
|
|
388 |
Keyword |
2022-11-16 |
|
|
389 |
CHEMICAL AND BIOLOGICAL EFFECTS OF AFLATOXINS |
2022-11-10 |
|
|
390 |
RISK ASSOCIATED WITH AFLATOXINS |
2022-11-10 |
|
|
391 |
AFLATOXIN CONTAMINATION PREVALENCE IN AGRICULTURAL PRODUCTS |
2022-11-10 |
|
|
392 |
CHARACTERISTICS OF AFLATOXINS |
2022-11-10 |
|
|
393 |
TYPES OF AFLATOXINS |
2022-11-10 |
|
|
394 |
PURPOSE OF THE STUDY |
2022-11-09 |
|
|
395 |
Etiology Diagnosis |
2022-11-09 |
|
|
396 |
PROBLEM STATEMENT |
2022-11-08 |
|
|
397 |
JUSTIFICATION |
2022-11-08 |
|
|
398 |
SOME COMMON USES OF MICROWAVE |
2022-10-29 |
|
|
399 |
MECHANISM OF MW-INDUCED HYPERTHERMIA |
2022-10-29 |
|
|
400 |
NORMAL AND MALIGNANT HUMAN TISSUE DIELECTRIC PROPERTIES |
2022-10-29 |
|
|
401 |
Limitation and Recommendations |
2022-10-28 |
|
|
402 |
Sample Availability |
2022-10-27 |
|
|
403 |
Data Availability Statement |
2022-10-27 |
|
|
404 |
Ethics Committee Statement |
2022-10-27 |
|
|
405 |
Author Agreement |
2022-10-27 |
|
|
406 |
Ethics Statement |
2022-10-27 |
|
|
407 |
Funding |
2022-10-27 |
|
|
408 |
Credit Authorship Contribution Statement |
2022-10-27 |
|
|
409 |
Acknowledgements (if any) |
2022-10-27 |
|
|
410 |
What this Study Adds |
2022-10-27 |
|
|
411 |
What is already known on this Topic |
2022-10-27 |
|
|
412 |
Resume |
2022-10-27 |
|
|
413 |
Outline |
2022-10-27 |
|
|
414 |
DISEASED SEEDLINGS |
2022-10-19 |
|
|
415 |
FUNGICIDE SEED TREATMENT |
2022-10-19 |
|
|
416 |
LOCAL AGROECOSYSTEM MODIFICATION |
2022-10-19 |
|
|
417 |
CASE B |
2022-10-14 |
|
|
418 |
CASE A |
2022-10-14 |
|
|
419 |
ARRHYTHMIAS AND TREATMENT |
2022-10-14 |
|
|
420 |
LINKING THE APPEARANCE OF A FUNGUS |
2022-10-13 |
|
|
421 |
Suggestions for Future Research |
2022-10-13 |
|
|
422 |
Discussion of Results |
2022-10-13 |
|
|
423 |
Periapical Bleeding |
2022-10-06 |
|
|
424 |
Regenerative Endodontics |
2022-10-06 |
|
|
425 |
Root Canal Fillings |
2022-10-06 |
|
|
426 |
Revascularization |
2022-10-06 |
|
|
427 |
Periodontopathogenic Biofilm |
2022-10-04 |
|
|
428 |
Oral Microbiomics |
2022-10-04 |
|
|
429 |
Oral Biofilms |
2022-10-04 |
|
|
430 |
Properties of Microbial Biofilms |
2022-10-04 |
|
|
431 |
Surface Decontamination |
2022-10-03 |
|
|
432 |
Infection and prevention control (IPC) |
2022-10-03 |
|
|
433 |
Differential Diagnosis |
2022-09-30 |
|
|
434 |
Follow-Up |
2022-09-30 |
|
|
435 |
Histopathology |
2022-09-30 |
|
|
436 |
FURTHER DISCUSSIONS AND CONSEQUENCES |
2022-09-23 |
|
|
437 |
STUDY METHODOLOGY |
2022-09-22 |
|
|
438 |
STUDY METHODOLOGY: |
2022-09-22 |
|
|
439 |
FEATURES OF THE INCLUDED STUDIES |
2022-09-21 |
|
|
440 |
Effects of the tongan volcanic aerosols |
2022-09-21 |
|
|
441 |
Terminal Illness |
2022-09-13 |
|
|
442 |
Discloures |
2022-09-13 |
|
|
443 |
Experimental Methods |
2022-09-12 |
|
|
444 |
Limitations and Recommendation |
2022-09-09 |
|
|
445 |
ANALYSIS AND PRESENTATION OF RESULTS |
2022-09-08 |
|
|
446 |
Ethical Clearance |
2022-09-07 |
|
|
447 |
Notification of Prior Presentation |
2022-09-07 |
|
|
448 |
Postoperative Care |
2022-08-29 |
|
|
449 |
Anaesthesia Technique |
2022-08-29 |
|
|
450 |
Conclusions and prospects for further research |
2022-08-18 |
|
|
451 |
Research results |
2022-08-18 |
|
|
452 |
Availability of the data |
2022-08-10 |
|
|
453 |
blication. CONFLICT OF INTEREST |
2022-08-05 |
|
|
454 |
SOURCE OF FINANCIAL GRANT |
2022-08-05 |
|
|
455 |
CONFLICT OF INTEREST |
2022-08-05 |
|
|
456 |
CONFLICT OF INTEREST |
2022-08-05 |
|
|
457 |
CONTRIBUTION OF AUTHORS |
2022-08-05 |
|
|
458 |
Neurostimulation and Peripheral Nerve Stimulation |
2022-08-03 |
|
|
459 |
Nerve Blocks, Rfa, Cryotherapy, Chemodenervation, Neurolysis |
2022-08-02 |
|
|
460 |
Interventional Pain Techniques For Cpps |
2022-08-01 |
|
|
461 |
Possible Mechanisms of Cpps |
2022-08-01 |
|
|
462 |
Biological Hazards |
2022-08-01 |
|
|
463 |
Brainstem and Basal Forebrain |
2022-08-01 |
|
|
464 |
Thalamus |
2022-08-01 |
|
|
465 |
Cerebral Cortex |
2022-08-01 |
|
|
466 |
Neuropathic Pain |
2022-08-01 |
|
|
467 |
Descending Pain Modulation |
2022-07-30 |
|
|
468 |
References |
2022-07-30 |
|
|
469 |
4. Acknowledgements |
2022-07-30 |
|
|
470 |
Conclusion |
2022-07-30 |
|
|
471 |
2. India |
2022-07-30 |
|
|
472 |
1. Background |
2022-07-30 |
|
|
473 |
References |
2022-07-30 |
|
|
474 |
Conclusion |
2022-07-30 |
|
|
475 |
4. Application Development |
2022-07-30 |
|
|
476 |
Result |
2022-07-30 |
|
|
477 |
2. EHR and EHR-S Evaluation Factors and Findings |
2022-07-30 |
|
|
478 |
Conclusion |
2022-07-30 |
|
|
479 |
8. Why Innovations do not Scale and the Way Forward |
2022-07-30 |
|
|
480 |
7. Digital Health Guidelines as a Framework for Futuristic Learning Health Systems |
2022-07-30 |
|
|
481 |
6. Digital Health Platforms as Early Warning Systems in Health Emergencies |
2022-07-30 |
|
|
482 |
5. Digital Platforms as Enablers for Universal Participation |
2022-07-30 |
|
|
483 |
4. Information as a Therapeutic Intervention for Achieving UHC |
2022-07-30 |
|
|
484 |
3. Information Asymmetries and its Impact on Health Systems |
2022-07-30 |
|
|
485 |
2. Current Strategies for Universal Health Coverage |
2022-07-30 |
|
|
486 |
Clinical Spectrum |
2022-07-29 |
|
|
487 |
Pathogenesis |
2022-07-29 |
|
|
488 |
Epidemiology and Risk Factors |
2022-07-29 |
|
|
489 |
Transmission |
2022-07-29 |
|
|
490 |
IMMUNOHISTOCHEMISTRY |
2022-07-28 |
|
|
491 |
LANGERHANS CELL HISTIOCYTOSIS |
2022-07-28 |
|
|
492 |
CHEMOPREVENTION |
2022-07-28 |
|
|
493 |
Primary Insufficiency of the Adrenal Glands |
2022-07-27 |
|
|
494 |
CASES |
2022-07-25 |
|
|
495 |
DATA AVAILABILITY STATEMENTS |
2022-07-25 |
|
|
496 |
Tooth Autotransplantation |
2022-07-25 |
|
|
497 |
Primary Root Canal Treatment |
2022-07-25 |
|
|
498 |
IMMUNITY AND COAGULATION |
2022-07-25 |
|
|
499 |
COLLECTION OF CLINICAL DATA |
2022-07-25 |
|
|
500 |
Modification of the gravity theory |
2022-07-23 |
|
|
501 |
Conclusions |
2022-07-22 |
|
|
502 |
GENE THERAPY |
2022-07-22 |
|
|
503 |
ALTERNATIVE THERAPIES |
2022-07-22 |
|
|
504 |
THE HEMOPHILIA REPLACEMENT THERAPY TARGETS |
2022-07-22 |
|
|
505 |
REPLACEMENT THERAPY |
2022-07-22 |
|
|
506 |
RED BLOOD CELL TRANSFUSION RECOMMENDATIONS |
2022-07-22 |
|
|
507 |
NANOMATERIALS IN THE FOOD INDUSTRY |
2022-07-21 |
|
|
508 |
NANOMATERIALS IN THE AGRIFOOD INDUSTRY |
2022-07-21 |
|
|
509 |
ETHICAL ISSUES |
2022-07-21 |
|
|
510 |
STANDARDS |
2022-07-21 |
|
|
511 |
TOXICITY TESTS AND CLINICAL TRIALS |
2022-07-21 |
|
|
512 |
MODELING |
2022-07-21 |
|
|
513 |
IMAGING |
2022-07-21 |
|
|
514 |
NANOINFORMATICS AREAS |
2022-07-21 |
|
|
515 |
NANOTECHNOLOGY AND NANOINFORMATICS |
2022-07-21 |
|
|
516 |
BIOMEDICAL INFORMATICS |
2022-07-21 |
|
|
517 |
NANOMATERIALS IN FOOD: TOXICOLOGICAL ASPECTS |
2022-07-21 |
|
|
518 |
ACTIVE FOOD PACKAGING SYSTEMS |
2022-07-21 |
|
|
519 |
FOOD PACKAGING WITH NANOTECHNOLOGY |
2022-07-21 |
|
|
520 |
NANOTECHNOLOGY IN FOOD PROCESSING |
2022-07-21 |
|
|
521 |
FOOD APPLICATIONS WITH POTENTIAL |
2022-07-21 |
|
|
522 |
OPPORTUNITIES |
2022-07-21 |
|
|
523 |
PURIFICATION OF CARBON NANOTUBES |
2022-07-21 |
|
|
524 |
SYNTHESIS TECHNIQUES OF CARBON NANOTUBES |
2022-07-21 |
|
|
525 |
PROPERTIES |
2022-07-21 |
|
|
526 |
Summary conclusion |
2022-07-18 |
|
|
527 |
Results/Discussions |
2022-07-18 |
|
|
528 |
Problem-solving observable physics |
2022-07-18 |
|
|
529 |
Publication of speakers |
2022-07-18 |
|
|
530 |
Lesson |
2022-07-18 |
|
|
531 |
Recent Publications |
2022-07-18 |
|
|
532 |
Types of Stem Cells |
2022-07-14 |
|
|
533 |
APPLICATION AND VERIFICATION: RADIUS OF MATTER ELEMENTARY PARTICLE |
2022-07-12 |
|
|
534 |
DEDUCTION |
2022-07-11 |
|
|
535 |
Past Confeernce Report |
2022-07-11 |
|
|
536 |
Seismic Units and Facies |
2022-07-08 |
|
|
537 |
Seismic Units and Facies |
2022-07-08 |
|
|
538 |
Seismic Units and Facies |
2022-07-08 |
|
|
539 |
2.Conclusion |
2022-07-01 |
|
|
540 |
References |
2022-07-01 |
|
|
541 |
Conclusion |
2022-07-01 |
|
|
542 |
References |
2022-07-01 |
|
|
543 |
9. Funding |
2022-07-01 |
|
|
544 |
8. Disclosure |
2022-07-01 |
|
|
545 |
7. Conclusion |
2022-07-01 |
|
|
546 |
6. Dimensional Data Model |
2022-07-01 |
|
|
547 |
5. Data Warehouse |
2022-07-01 |
|
|
548 |
4. Advantages of the Relational Data Model |
2022-07-01 |
|
|
549 |
3. Predicate Logic and Set Theory |
2022-07-01 |
|
|
550 |
2.Relational Data Model |
2022-07-01 |
|
|
551 |
1.Introduction |
2022-07-01 |
|
|
552 |
VIRUS TROPISM AND PATHOGENESIS |
2022-06-30 |
|
|
553 |
CLINICAL SYMPTOMS |
2022-06-30 |
|
|
554 |
THE VIRUS, ITS ORIGINS AND EVOLUTION |
2022-06-30 |
|
|
555 |
CO-INFECTION BY MULTIPLE VIRUSE |
2022-06-30 |
|
|
556 |
VIRAL NUCLEIC ACID DETECTION |
2022-06-30 |
|
|
557 |
SEROLOGICAL ASSAYS |
2022-06-30 |
|
|
558 |
MOLECULAR SCREENING |
2022-06-30 |
|
|
559 |
Expansion By Infected Tick |
2022-06-30 |
|
|
560 |
Serology |
2022-06-30 |
|
|
561 |
Role of Intima |
2022-06-30 |
|
|
562 |
Past |
2022-06-30 |
|
|
563 |
INTRODUCTION |
2022-06-28 |
|
|
564 |
Skeletal Malformations |
2022-06-24 |
|
|
565 |
Natural clinical course |
2022-06-24 |
|
|
566 |
Vascular access and regional anesthesia |
2022-06-24 |
|
|
567 |
Airway Management |
2022-06-24 |
|
|
568 |
PERSPECTRIVE |
2022-06-23 |
|
|
569 |
ADRENAL GLAND |
2022-06-21 |
|
|
570 |
PITUITARY GLAND |
2022-06-21 |
|
|
571 |
CHEMICALS NEED TO BE AVOID |
2022-06-21 |
|
|
572 |
DICHOTOMOUS CLASSIFICATION (TAXONOMY) OF PSYCHOLOGICAL THEORIES |
2022-06-16 |
|
|
573 |
Publications |
2022-06-15 |
|
|
574 |
Suggestions/Recommendations |
2022-06-08 |
|
|
575 |
SYNTHETIC SEED PRODUCTION |
2022-05-31 |
|
|
576 |
CONCLUSIONS AND PERSPECTIVES |
2022-05-31 |
|
|
577 |
OXIDATIVE THF BREAKDOWN |
2022-05-31 |
|
|
578 |
THE ROLE OF NANOTECHNOLOGY IN IMMUNOTHERAPY IN HER2-POSITIVE BREAST CANCER |
2022-05-26 |
|
|
579 |
SMALL MOLECULE TYROSINE KINASE INHIBITORS (SMTKIS) |
2022-05-26 |
|
|
580 |
ANTIBODY DRUG CONJUGATES (ADCS) |
2022-05-26 |
|
|
581 |
PERTUZUMAB |
2022-05-26 |
|
|
582 |
LARGE MOLECULE TYROSINE KINASE INHIBITORS (TKI) |
2022-05-26 |
|
|
583 |
Analytical Methods |
2022-05-25 |
|
|
584 |
Observational Study |
2022-05-24 |
|
|
585 |
QUALITY CONTROL AND STATISTICAL ANALYSIS |
2022-05-21 |
|
|
586 |
INTERESTED OUTCOMES |
2022-05-21 |
|
|
587 |
SEARCHING THE LITERATURE AND CHOOSING A STUDY |
2022-05-21 |
|
|
588 |
PATHOLOGIC FINDINGS AND PATIENTS |
2022-05-21 |
|
|
589 |
THE TUMOR'S LOCALIZATION |
2022-05-20 |
|
|
590 |
REPRODUCTIVE AGING |
2022-05-20 |
|
|
591 |
YOUNG WOMEN'S REPRODUCTIVE AXIS |
2022-05-20 |
|
|
592 |
REASONS FOR THE SUMMIT ON DIABETES SURGERY |
2022-05-20 |
|
|
593 |
HOW TO MANAGE ANGER IN CHILDREN? |
2022-05-19 |
|
|
594 |
WHAT ARE THE REASONS BEHIND ANGER IN CHILDREN? |
2022-05-19 |
|
|
595 |
ANALYSIS ON DRUG DISCOVERY |
2022-05-16 |
|
|
596 |
Drug Delivery Technologies Pharmaceutical Delivery |
2022-05-13 |
|
|
597 |
Pharmaceutical Analysis and Developments |
2022-05-13 |
|
|
598 |
Drug Discovery and Development |
2022-05-13 |
|
|
599 |
DRUG TOXICOLOGY |
2022-05-13 |
|
|
600 |
DIFFERENT BACTERIAL STRAINS FOUND AS CONTAMINANTS IN MILK |
2022-05-12 |
|
|
601 |
PREPARATION OF REAL SAMPLES |
2022-05-11 |
|
|
602 |
Mechanisms mediating cell plasticity |
2022-05-11 |
|
|
603 |
POTENTIAL OPPORTUNITIES IN THE DENTAL SERVICES MARKET |
2022-05-09 |
|
|
604 |
DENTAL SERVICES MARKET SEGMENTATION |
2022-05-09 |
|
|
605 |
DENTAL SERVICES MARKET SIZE |
2022-05-09 |
|
|
606 |
DENTAL SERVICES MARKET COMPETITIVE LANDSCAPE |
2022-05-09 |
|
|
607 |
EXPERIMENTAL PART |
2022-05-09 |
|
|
608 |
Grant Information |
2022-05-06 |
|
|
609 |
HCV Proteins |
2022-05-06 |
|
|
610 |
Industrial trans-fatty acid intake and the risk of coronary heart disease |
2022-05-06 |
|
|
611 |
High Molecular Weight with Low Concentration Has an Impact on Immunity and Cancer |
2022-05-06 |
|
|
612 |
Higher Beta-Glucan Viscosity and Better Post-Prandial Glucose Metabolism |
2022-05-06 |
|
|
613 |
High Molecular Weight Beta-Glucan Contributes towards better Cholesterol Control and Better Cardiovascular Outcomes |
2022-05-06 |
|
|
614 |
Medications and multifunctional products with phosphatidylserine: A very well cognitive solution |
2022-05-06 |
|
|
615 |
REGULATING NANOROBOTS |
2022-05-05 |
|
|
616 |
Management During Pregnancy |
2022-05-04 |
|
|
617 |
Nanodentistry |
2022-05-04 |
|
|
618 |
Clinical Features |
2022-05-03 |
|
|
619 |
Pheochromocytoma |
2022-05-03 |
|
|
620 |
ONCOLOGY NURSING |
2022-05-02 |
|
|
621 |
UROGYNAECOLOGY |
2022-05-02 |
|
|
622 |
FEMALE AND GENITAL MUTILATION |
2022-05-02 |
|
|
623 |
TREATMENT FOR DIABETES |
2022-04-30 |
|
|
624 |
CVD RISK REDUCTION RESEARCH |
2022-04-30 |
|
|
625 |
LIPID RELATED DANGERS |
2022-04-30 |
|
|
626 |
POTENTIAL NANOROBOT HAZARDS |
2022-04-28 |
|
|
627 |
TECHNOLOGICAL DEVELOPMENT OF NANOROBOTS |
2022-04-28 |
|
|
628 |
BIOPSY |
2022-04-28 |
|
|
629 |
WOUND HEALING |
2022-04-28 |
|
|
630 |
TRANSPORT AND RELEASE OF CELLS |
2022-04-28 |
|
|
631 |
THERAPEUTIC AND IMAGING AGENTS FOR CANCER THERAPY |
2022-04-28 |
|
|
632 |
in vivo NANOROBOTIC APPLICATIONS |
2022-04-28 |
|
|
633 |
PREVENTIVE, COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY |
2022-04-25 |
|
|
634 |
DENTAL BIOMATERIALS AND BIOENGINEERING |
2022-04-25 |
|
|
635 |
Key Words: |
2022-04-19 |
|
|
636 |
Result |
2022-04-19 |
|
|
637 |
RBC MEMBRANE-COATED POLYMERIC NANOPARTICLES |
2022-04-13 |
|
|
638 |
RED BLOOD CELL (RBC)-BASED SYSTEMS AS LONG-CIRCULATING DRUG CARRIERS |
2022-04-13 |
|
|
639 |
CONCLUSION AND FUTURE OUTLOOK |
2022-04-13 |
|
|
640 |
ENGINEERED NANOPARTICLES |
2022-04-13 |
|
|
641 |
GENERAL PHARMACOKINETIC CHARACTERISTICS OF NANODRUGS |
2022-04-13 |
|
|
642 |
INTRODUCTION |
2022-04-13 |
|
|
643 |
PERSPECTIVES FOR THE FUTURE |
2022-04-13 |
|
|
644 |
RECENT DEVELOPMENTS |
2022-04-12 |
|
|
645 |
ONCOLOGY |
2022-04-12 |
|
|
646 |
HEMATOLOGY |
2022-04-12 |
|
|
647 |
MICROBIOLOGY |
2022-04-12 |
|
|
648 |
THE MECHANISM OF COFFEE’S HEPATOPROTECTIVE EFFECT |
2022-04-06 |
|
|
649 |
ABSTRACT |
2022-04-06 |
|
|
650 |
Keywords |
2022-04-06 |
|
|
651 |
COFFEE |
2022-04-06 |
|
|
652 |
RECOMMENDATION. |
2022-03-30 |
|
|
653 |
LITERATURE REVIEW. |
2022-03-30 |
|
|
654 |
AIM OF THE PAPER |
2022-03-30 |
|
|
655 |
Consent to Publication |
2022-03-22 |
|
|
656 |
AUTHOR’S INFORMATION |
2022-03-22 |
|
|
657 |
CLINICAL FEATURE |
2022-03-15 |
|
|
658 |
Key Words |
2022-03-10 |
|
|
659 |
Low Store and Amassing at the Cancer Locale and Serious After effects |
2022-03-04 |
|
|
660 |
Repair of Bone |
2022-02-28 |
|
|
661 |
Breast-Q |
2022-02-28 |
|
|
662 |
FUTURE ASPECTS |
2022-02-28 |
|
|
663 |
Nucleosides Can Be Phosphorylated By Explicit Kinases in the Cell, Delivering Nucleotides |
2022-02-25 |
|
|
664 |
Pyrrolysine Is Combined Into Specific Proteins at A UAG Codon |
2022-02-25 |
|
|
665 |
The Least Demanding Kind of Sugar Is a Monosaccharide |
2022-02-25 |
|
|
666 |
They Give the Plan of Cells and Play out An Extensive Parcel of the Limits Related with Life |
2022-02-25 |
|
|
667 |
Around 150 Quassinoids Have Been Separated Relies Upon Their Substance Structures |
2022-02-23 |
|
|
668 |
It is a Complex Organic Liquid, Which Helps in the Improvement of Resistance in the Infant |
2022-02-23 |
|
|
669 |
Characterizing Dietary Fiber is a Different Interaction and is Subject to Both Sustenance and Scientific Ideas |
2022-02-23 |
|
|
670 |
Cell Viability was Measured Using the MTT Assay |
2022-02-23 |
|
|
671 |
Inductively coupled plasma (ICP) arrangement |
2022-02-23 |
|
|
672 |
Decomposition and Analysis Data هه |
2022-02-22 |
|
|
673 |
Hypothesis Main |
2022-02-22 |
|
|
674 |
Common Language of All Nations Mathematics |
2022-02-22 |
|
|
675 |
Solution |
2022-02-22 |
|
|
676 |
Derivation of Modified Variational Iteration Method and Fourier series of Periodic Function with a Period 2 for Solving Non-Homogeneous Ordinary Differential Equations |
2022-02-22 |
|
|
677 |
Digital Waveguide Modeling of the Vocal Tract |
2022-02-22 |
|
|
678 |
Gibbs Sampling |
2022-02-22 |
|
|
679 |
Issues of Repeated Game |
2022-02-22 |
|
|
680 |
|
2022-02-21 |
|
|
681 |
To ensure the proper replication of cell additives and department |
2022-02-17 |
|
|
682 |
Chemotherapy is one of the essential categories of the medical area |
2022-02-17 |
|
|
683 |
Maximum oncogenes started as proto-oncogenes: normal genes involved in mobile growth |
2022-02-17 |
|
|
684 |
Vasculogenesis is the embryonic formation of endothelial cells |
2022-02-17 |
|
|
685 |
The technique involves extraction of pattern cells or tissues |
2022-02-17 |
|
|
686 |
ROLES AND RESPONSIBILITY |
2022-02-15 |
|
|
687 |
Model Development |
2022-02-09 |
|
|
688 |
Study Procedures |
2022-02-09 |
|
|
689 |
Ethical Committie |
2022-02-08 |
|
|
690 |
Statistical Analysis and Results |
2022-02-08 |
|
|
691 |
Conclusion |
2022-02-03 |
|
|
692 |
Abreviations |
2022-01-10 |
|
|
693 |
Result and Disscussion |
2022-01-10 |
|
|
694 |
Systematic Review Supports Value of Communication Skills and PPR |
2022-01-04 |
|
|
695 |
Methods of Bone Grafting |
2022-01-04 |
|
|
696 |
test |
2021-12-31 |
|
|
697 |
Informed Consent |
2021-12-30 |
|
|
698 |
Conflicts Of Interest |
2021-12-30 |
|
|
699 |
Compliance With Ethical Standards |
2021-12-30 |
|
|
700 |
The Subjective Nature of Dreams |
2021-12-29 |
|
|
701 |
Symptoms and Identification |
2021-12-27 |
|
|
702 |
Diagnosis and Treatment |
2021-12-27 |
|
|
703 |
Types |
2021-12-27 |
|
|
704 |
Causes and Symptoms |
2021-12-27 |
|
|
705 |
Osteosarcoma Treatment |
2021-12-23 |
|
|
706 |
Subtypes of Osteosarcoma |
2021-12-23 |
|
|
707 |
Rules for young researchers forum |
2021-12-16 |
|
|
708 |
Hematology Congress 2022 Young Scientist Awards |
2021-12-16 |
|
|
709 |
Why to join the event? |
2021-12-16 |
|
|
710 |
About Conference |
2021-12-16 |
|
|
711 |
Challenges Related to Water Management in Agriculture |
2021-12-14 |
|
|
712 |
Management of Alkaline Soil |
2021-12-13 |
|
|
713 |
Effect of Alkalinity on Physical and Chemical Properties of Soil |
2021-12-13 |
|
|
714 |
Soil Alkalinity and Sources of Alkalinity |
2021-12-13 |
|
|
715 |
Recent Studies Suggest That Dop Agonist May Have Biased Ligands |
2021-12-10 |
|
|
716 |
Facilitating Effects on Fear Extinction Learning Observed With Dop Agonists |
2021-12-10 |
|
|
717 |
Current Status and Issues in the Development of Therapeutic Drugs for Ptsd |
2021-12-10 |
|
|
718 |
Stem Cell Overview |
2021-12-10 |
|
|
719 |
Fault Seal Assessment |
2021-12-09 |
|
|
720 |
Geophysical Interpretation |
2021-12-09 |
|
|
721 |
Risk Factors for Patients with Hematologic Malignancies |
2021-12-08 |
|
|
722 |
Fish Preservation Methods |
2021-12-02 |
|
|
723 |
Antibiotic Resistance |
2021-12-02 |
|
|
724 |
Foodborne Diseases |
2021-12-02 |
|
|
725 |
Microflora of Fish and Fish Environments |
2021-12-02 |
|
|
726 |
Bacterial Fish Contamination |
2021-12-02 |
|
|
727 |
Fish Contamination |
2021-12-02 |
|
|
728 |
Surrogacy |
2021-11-26 |
|
|
729 |
Cryopreservation |
2021-11-26 |
|
|
730 |
Conflicts of Insterest |
2021-11-25 |
|
|
731 |
Author Information |
2021-11-25 |
|
|
732 |
Animal Ethical Approval |
2021-11-25 |
|
|
733 |
Ethics Declarations |
2021-11-25 |
|
|
734 |
Availability of Data any Material |
2021-11-25 |
|
|
735 |
Determination of Floating Behavior |
2021-11-20 |
|
|
736 |
Sensory Test |
2021-11-20 |
|
|
737 |
Particle Size And Morphology Evaluation |
2021-11-20 |
|
|
738 |
Application to A Clinical Pharmacokinetic Study |
2021-11-20 |
|
|
739 |
Arrangement of Plant Extricates |
2021-11-20 |
|
|
740 |
Editotrial Note |
2021-11-12 |
|
|
741 |
Test for Leprosy |
2021-11-11 |
|
|
742 |
Causes and Treatment |
2021-11-11 |
|
|
743 |
Symptoms and Treatment |
2021-11-11 |
|
|
744 |
Types and Causes of Skin Cancer |
2021-11-11 |
|
|
745 |
Steps For Mipo Technique |
2021-11-10 |
|
|
746 |
Surgical Steps For Supracutaneous Plating |
2021-11-10 |
|
|
747 |
Sine Gordon Expansion Method |
2021-11-09 |
|
|
748 |
Characteristics That Were Selected For Experiment |
2021-11-05 |
|
|
749 |
Selection of the Experimental Plants |
2021-11-05 |
|
|
750 |
Convergence Conditions |
2021-11-03 |
|
|
751 |
System of Linear Equations |
2021-11-03 |
|
|
752 |
Direct and Interactive Methods for Solving a System of Linear Equations |
2021-11-03 |
|
|
753 |
Social media a fresh platform for futuristic surgical learning: Overview |
2021-10-27 |
|
|
754 |
Is minimal invasive technique in cardiac surgery preferable over traditional technique? |
2021-10-27 |
|
|
755 |
Mental willingness, PTSD and surgical outcomes correlation: Overview |
2021-10-27 |
|
|
756 |
Pre-surgical opioid prescriptions leading to chronic opioid abuse |
2021-10-27 |
|
|
757 |
Women underrepresentation in surgical field: Overview |
2021-10-27 |
|
|
758 |
Accessibility of the Healthcare |
2021-10-26 |
|
|
759 |
Animal-Related Diseases |
2021-10-26 |
|
|
760 |
Vector-Borne Diseases |
2021-10-26 |
|
|
761 |
Sexually Transmitted Infections (STIs) |
2021-10-26 |
|
|
762 |
Hepatitis A |
2021-10-26 |
|
|
763 |
Infectious Disease Risks for Qatar 2022 Attendees and Disease-Specific Prevention Recommendations |
2021-10-26 |
|
|
764 |
Pretravel Health Care and vaccination |
2021-10-26 |
|
|
765 |
Sagittal plane - Non-structural misalignments of body posture |
2021-10-26 |
|
|
766 |
Acute Traumatic Coagulopathy |
2021-10-26 |
|
|
767 |
Chondroradionecrosis of the Larynx |
2021-10-26 |
|
|
768 |
Editorial Note on Hip arthroplasty |
2021-10-26 |
|
|
769 |
History of Organ Transplantation |
2021-10-26 |
|
|
770 |
Development of microfluidic devices for fertility |
2021-10-21 |
|
|
771 |
Methods of Echocardiogram |
2021-10-19 |
|
|
772 |
Deformities of Echocardiogram |
2021-10-19 |
|
|
773 |
Pulmonary Circulation |
2021-10-19 |
|
|
774 |
Survey And Feedback |
2021-10-19 |
|
|
775 |
Memberships And Reprints |
2021-10-19 |
|
|
776 |
Advertisement Platform |
2021-10-19 |
|
|
777 |
Submission Process |
2021-10-19 |
|
|
778 |
Article Types |
2021-10-19 |
|
|
779 |
SLI Disorder with Multiple Underlying Deficits |
2021-10-18 |
|
|
780 |
Clinical suggestions |
2021-10-18 |
|
|
781 |
Genetic influences on different aspects of Language Impairment |
2021-10-18 |
|
|
782 |
Acute Bacterial Meningitis |
2021-10-18 |
|
|
783 |
Extra-axial empyema |
2021-10-18 |
|
|
784 |
Neuropsychological interventions |
2021-10-18 |
|
|
785 |
Etiology and pathophysiology |
2021-10-18 |
|
|
786 |
Ultrasound-guided central line insertion |
2021-10-18 |
|
|
787 |
Ultrasound and cystic hygroma |
2021-10-18 |
|
|
788 |
Ultrasonography techniques |
2021-10-18 |
|
|
789 |
Dissociative Amnesia Treated |
2021-10-18 |
|
|
790 |
Moral misery of NICU staff |
2021-10-18 |
|
|
791 |
Dissociative Amnesia Diagnosed |
2021-10-18 |
|
|
792 |
Effect of a pandemic on the NICU |
2021-10-18 |
|
|
793 |
Contemplations on life-and-demise choices during a pandemic |
2021-10-18 |
|
|
794 |
Ordinary life-and-passing dynamic in the NICU |
2021-10-18 |
|
|
795 |
Early learning and childcare practitioner |
2021-10-18 |
|
|
796 |
Theories of child development |
2021-10-18 |
|
|
797 |
Child development |
2021-10-18 |
|
|
798 |
Adult Changes in Thought (ACT) |
2021-10-18 |
|
|
799 |
Challenges of activation of adult NSCs |
2021-10-18 |
|
|
800 |
Age-dependent decrease in neural stem cells and adult neurogenesis |
2021-10-18 |
|
|
801 |
Origin of adult NSCs |
2021-10-18 |
|
|
802 |
Systemic Circulatory System |
2021-10-14 |
|
|
803 |
Short Commentary |
2021-10-08 |
|
|
804 |
Impacts of atmospheric black carbon on climate |
2021-10-08 |
|
|
805 |
A remedy to global warming and the energy crisis |
2021-10-08 |
|
|
806 |
Environmentally sustainable chemistry |
2021-10-08 |
|
|
807 |
Vehicle pollutes the atmosphere and poses health hazards |
2021-10-08 |
|
|
808 |
Radioactive pollution in environment |
2021-10-08 |
|
|
809 |
AIDS |
2021-09-30 |
|
|
810 |
The Primordial Cells and Metabolism |
2021-09-30 |
|
|
811 |
Acne and the Menstrual Cycle |
2021-09-30 |
|
|
812 |
Types of Cancer |
2021-09-30 |
|
|
813 |
Applications |
2021-09-29 |
|
|
814 |
short |
2021-09-27 |
|
|
815 |
LETTER |
2021-09-14 |
|
|
816 |
Viewpoint |
2021-09-09 |
|
|
817 |
Diagnosis Observations |
2021-09-07 |
|
|
818 |
Classification of Tooth Fractures by Talim and Gohil |
2021-09-07 |
|
|
819 |
Types of Furcation Fractures |
2021-09-07 |
|
|
820 |
Perfadex Solution |
2021-09-06 |
|
|
821 |
IGL-1 Solution |
2021-09-06 |
|
|
822 |
Kyoto University Preservation Solution |
2021-09-06 |
|
|
823 |
Celsior Solution |
2021-09-06 |
|
|
824 |
Bretschneider's (Custodiol) Solution |
2021-09-06 |
|
|
825 |
Citrate Solutions (Marshall/Ross) |
2021-09-06 |
|
|
826 |
University of Wisconsin Solution (UW) |
2021-09-06 |
|
|
827 |
Collins Solution |
2021-09-06 |
|
|
828 |
Preservation Solutions |
2021-09-06 |
|
|
829 |
Author's Contribution |
2021-09-06 |
|
|
830 |
Subject |
2021-09-03 |
|
|
831 |
Microorganisms Utilized to Change Over the Lactose Sugars into Lactic Corrosive |
2021-09-01 |
|
|
832 |
Clinical and Vaccine Immunology Improves Comprehension of Resistant |
2021-09-01 |
|
|
833 |
Recombinant DNA Innovation Utilizes Microorganisms |
2021-09-01 |
|
|
834 |
Antigens Regularly Lead to a Resistant Reaction of Tumor |
2021-09-01 |
|
|
835 |
Pathogenic Organisms Challenge the Insusceptible Framework |
2021-09-01 |
|
|
836 |
The significant site of CSF development is the choroid plexus |
2021-09-01 |
|
|
837 |
Hypospadias Influences Around 1 In Each 500 Infant Boys |
2021-08-31 |
|
|
838 |
Embryonic Undifferentiated Organisms Can Separate Into More Cell |
2021-08-31 |
|
|
839 |
Pre-Birth Conclusion Implies Determination Before Birth |
2021-08-31 |
|
|
840 |
Single Cell Cluster Comparative Genomic Hybridisation Exhibit |
2021-08-31 |
|
|
841 |
Ultrastructure Investigations of Creating Muscle By Transmission Electron Microscopy |
2021-08-31 |
|
|
842 |
Enzyme Inhibition |
2021-08-30 |
|
|
843 |
Anticancer |
2021-08-30 |
|
|
844 |
Antioxidant |
2021-08-30 |
|
|
845 |
Anti-Inflammatory |
2021-08-30 |
|
|
846 |
Applications of Flavinoids |
2021-08-30 |
|
|
847 |
Pathologic exam of a biopsy |
2021-08-30 |
|
|
848 |
Anti-Cancer drugs as part of chemotherapy regimen |
2021-08-30 |
|
|
849 |
Oncogene can also an cellular to secrete boom factors |
2021-08-30 |
|
|
850 |
Carcinoma is extra dependent on the size of tumor |
2021-08-30 |
|
|
851 |
Possible signs and symptoms encompass lump |
2021-08-30 |
|
|
852 |
Symptoms of Psoriasis |
2021-08-27 |
|
|
853 |
Prescribing Pattern |
2021-08-27 |
|
|
854 |
Source(S) of Support/Funding |
2021-08-25 |
|
|
855 |
From or to Icu |
2021-08-25 |
|
|
856 |
Postpone Nonessential Surgeries |
2021-08-25 |
|
|
857 |
Personal Protective Equipment |
2021-08-25 |
|
|
858 |
Role of Anesthesiologist |
2021-08-25 |
|
|
859 |
In Closing |
2021-08-24 |
|
|
860 |
The Relation between the Diaphragm, the Heart and the Kidneys |
2021-08-24 |
|
|
861 |
The Diaphragm’s Influence on the Release of Atrial Natriuretic Peptide |
2021-08-24 |
|
|
862 |
The Stimulus for the Release of Atrial Natriuretic Peptide |
2021-08-24 |
|
|
863 |
The Absence of Atrial Natriuretic Peptide and the Kidneys |
2021-08-24 |
|
|
864 |
The Positive Effect that Atrial Natriuretic Peptide has on the Kidneys |
2021-08-24 |
|
|
865 |
Atrial Natriuretic Peptide |
2021-08-24 |
|
|
866 |
Ethics Compliance |
2021-08-24 |
|
|
867 |
Endpoints |
2021-08-24 |
|
|
868 |
Alcohol Consumption |
2021-08-20 |
|
|
869 |
Image Analysis |
2021-08-17 |
|
|
870 |
Methods and Result Of Dissection |
2021-08-16 |
|
|
871 |
Method |
2021-08-16 |
|
|
872 |
Emotional Well-Being of HIV/AIDS Patients |
2021-08-16 |
|
|
873 |
Editorial note on Profoundly Active Anti-Retroviral Therapy |
2021-08-16 |
|
|
874 |
HIV/AIDS to HIV Cancer |
2021-08-16 |
|
|
875 |
Indirect Way |
2021-08-13 |
|
|
876 |
Direct Way |
2021-08-13 |
|
|
877 |
Classification of Lumbar Spinal Stenosis |
2021-08-13 |
|
|
878 |
Method and Materials |
2021-08-13 |
|
|
879 |
Technique |
2021-08-12 |
|
|
880 |
Association of Bisphenol-A with Neuro Developmental Disorders |
2021-08-12 |
|
|
881 |
Effective Measurement of Bisphenol-A |
2021-08-12 |
|
|
882 |
Bisphenol-A |
2021-08-12 |
|
|
883 |
Case Representation |
2021-08-12 |
|
|
884 |
Goals and Objectives |
2021-08-10 |
|
|
885 |
Aims and Scope |
2021-08-10 |
|
|
886 |
Innovation |
2021-08-10 |
|
|
887 |
Current opinion |
2021-08-09 |
|
|
888 |
Emerging Role of Robotics in Skull Base Surgery |
2021-08-09 |
|
|
889 |
Advantages and Drawbacks of Surgery in Treatment of Gastro Esophageal Reflux: An Overview |
2021-08-09 |
|
|
890 |
Evolution of Micro vascular Surgery: An Overview |
2021-08-09 |
|
|
891 |
Molecular Fluorescence Imaging to Assist Surgery |
2021-08-09 |
|
|
892 |
Hydroxyurea |
2021-08-07 |
|
|
893 |
Chronic Complications |
2021-08-07 |
|
|
894 |
Acute Complications |
2021-08-07 |
|
|
895 |
Health Maintenance |
2021-08-07 |
|
|
896 |
Opinion Article |
2021-08-07 |
|
|
897 |
Editorial Note for Surgery: Case Reports Journal |
2021-08-07 |
|
|
898 |
EFFECTS ON FERTILITY |
2021-08-06 |
|
|
899 |
Symptoms |
2021-08-06 |
|
|
900 |
Causes |
2021-08-06 |
|
|
901 |
Mini Review |
2021-08-06 |
|
|
902 |
Brief Report |
2021-07-31 |
|
|
903 |
Prime Focus |
2021-07-29 |
|
|
904 |
Current Regulatory Requirements for Absence of Mycoplasma in Vaccines for Human Use |
2021-07-27 |
|
|
905 |
Pharmacopeial Specifications for Testing of Mycoplasma |
2021-07-27 |
|
|
906 |
Mycoplasma Testing Methods |
2021-07-27 |
|
|
907 |
Ocular Manifestations |
2021-07-27 |
|
|
908 |
Assurance of MIC |
2021-07-27 |
|
|
909 |
Editorial Note on Multidrug Resistant |
2021-07-27 |
|
|
910 |
Funding Disclosure |
2021-07-20 |
|
|
911 |
Limitations and Problems |
2021-07-20 |
|
|
912 |
Pain and Altered Mental Status |
2021-07-20 |
|
|
913 |
Therapy and Prevention |
2021-07-19 |
|
|
914 |
Diagnostic Challenge |
2021-07-19 |
|
|
915 |
Disorder of Social Behaviour |
2021-07-19 |
|
|
916 |
Symptoms Overlap ADHD and SUD |
2021-07-19 |
|
|
917 |
Neurological Complications |
2021-07-19 |
|
|
918 |
Linked Alterations in Gray and White Matter Morphology in Adults Withhigh-Functioning Autism Spectrum Disorder |
2021-07-14 |
|
|
919 |
ANNOUNCEMENT: CALL FOR PAPER |
2021-07-14 |
|
|
920 |
Ethics of Human and Animal Experiments |
2021-06-30 |
|
|
921 |
Policy Issues |
2021-06-30 |
|
|
922 |
Observation and Results |
2021-06-30 |
|
|
923 |
Data Collection |
2021-06-15 |
|
|
924 |
Toxicity |
2021-06-14 |
|
|
925 |
Pharmacogenetic Effect |
2021-06-14 |
|
|
926 |
Review on Acute Myeloid Leukemia |
2021-06-09 |
|
|
927 |
Thrombophlebitis |
2021-06-03 |
|
|
928 |
Pathophysiology of Varicose Veins |
2021-06-03 |
|
|
929 |
INTRODUCTION |
2021-06-03 |
|
|
930 |
Case-2 |
2021-06-03 |
|
|
931 |
Case-1 |
2021-06-03 |
|
|
932 |
Eligibility Criteria for Young Scientist Awards: Probiotics Asia Pacific 2021 |
2021-06-03 |
|
|
933 |
About Conference Series |
2021-06-03 |
|
|
934 |
Future of DNA analysis |
2021-05-16 |
|
|
935 |
Clinical application of DNA microarray |
2021-05-16 |
|
|
936 |
Applications of machine learning in multiple fields |
2021-05-16 |
|
|
937 |
How do we estimate Visualization Techniques? |
2021-05-16 |
|
|
938 |
Materilas and Methods |
2021-05-14 |
|
|
939 |
Analytical Techniques |
2021-05-12 |
|
|
940 |
Advances in Analytical Toxicology |
2021-05-12 |
|
|
941 |
Factors Influencing Toxicology |
2021-05-12 |
|
|
942 |
About the Study |
2021-05-04 |
|
|
943 |
The Emerging Spectrum of Covid-19 Neurology |
2021-05-03 |
|
|
944 |
Neuropathological Features of Covid-19 |
2021-05-03 |
|
|
945 |
Covid-19 and Acute Ischemic Stroke |
2021-05-03 |
|
|
946 |
Age and Stroke |
2021-05-03 |
|
|
947 |
Microbleeds |
2021-05-03 |
|
|
948 |
Showcasing and Patient Hopes |
2021-04-27 |
|
|
949 |
Vital Things for Patients |
2021-04-27 |
|
|
950 |
Declaration Statements |
2021-04-27 |
|
|
951 |
Conclusions and Recommendations |
2021-04-27 |
|
|
952 |
Data Collection and Analysis |
2021-04-26 |
|
|
953 |
Objective of the Study |
2021-04-26 |
|
|
954 |
Blood Sampling Methods |
2021-04-26 |
|
|
955 |
Methodology and Problem |
2021-04-26 |
|
|
956 |
Consent for Publishing |
2021-04-22 |
|
|
957 |
Multidisciplinary Treatment Planning and Execution |
2021-04-21 |
|
|
958 |
Multi-environment evaluation and genotype x environment interaction analysis of sorghum [sorghum bicolor (l.) Moench] genotypes in highland areas of ethiopia |
2021-04-19 |
|
|
959 |
Abbrevations |
2021-04-16 |
|
|
960 |
Bioleaching is Influenced by A Number of Factors |
2021-04-15 |
|
|
961 |
Prevention and Control |
2021-04-15 |
|
|
962 |
Editorials |
2021-04-15 |
|
|
963 |
Classification of Hydrochemical Facies |
2021-04-15 |
|
|
964 |
Evaluation of Irrigation Water Indices |
2021-04-15 |
|
|
965 |
Evaluation of Drinking Water Quality |
2021-04-15 |
|
|
966 |
Hydrogeochemical Analysis Results and Interpretation |
2021-04-15 |
|
|
967 |
Depth to Water and Aquifer Thickness |
2021-04-15 |
|
|
968 |
Correlation of Geo-Electric Log and Lithology Log |
2021-04-15 |
|
|
969 |
Hydrochemical Investigation |
2021-04-15 |
|
|
970 |
Vertical Electrical Sounding Survey (VES) |
2021-04-15 |
|
|
971 |
Geology and Hydrogeology |
2021-04-15 |
|
|
972 |
Description of the Study Area |
2021-04-15 |
|
|
973 |
Selection of an Antidepressant Medication |
2021-04-14 |
|
|
974 |
Drug Use |
2021-04-14 |
|
|
975 |
Drug Screening |
2021-04-14 |
|
|
976 |
Stages of Drug Development |
2021-04-14 |
|
|
977 |
Treatment of Infertility |
2021-04-07 |
|
|
978 |
Female Fertility Triggers |
2021-04-07 |
|
|
979 |
Male Infertility Causes |
2021-04-07 |
|
|
980 |
Progenesis |
2021-04-07 |
|
|
981 |
Clinical Characteristics |
2021-04-07 |
|
|
982 |
Is it Possible to Avoid Genetic Abnormalities? |
2021-04-07 |
|
|
983 |
Fetal Genetic Disorders |
2021-04-07 |
|
|
984 |
Different Types of Disorders Developed During Pregnancy |
2021-04-07 |
|
|
985 |
How to Avoid Endocrine Disruptors? |
2021-04-07 |
|
|
986 |
Effects of Endocrine Disruptors |
2021-04-07 |
|
|
987 |
Different Sources for Endocrine Disruptors |
2021-04-07 |
|
|
988 |
Various types of Endocrine Disruptors |
2021-04-07 |
|
|
989 |
Conclusion Remarks and Future Predictions |
2021-04-07 |
|
|
990 |
Main Results |
2021-04-07 |
|
|
991 |
Methodology of Analysis |
2021-04-07 |
|
|
992 |
Approximation of Functions |
2021-04-07 |
|
|
993 |
Function Interpolation |
2021-04-07 |
|
|
994 |
Basic Terms |
2021-04-07 |
|
|
995 |
Eccenticity |
2021-04-07 |
|
|
996 |
Prevention to Control Soil Erosion |
2021-04-06 |
|
|
997 |
Operative Methods |
2021-04-02 |
|
|
998 |
Abstact |
2021-04-02 |
|
|
999 |
What is the Ideal Eccentric Compression System? |
2021-03-29 |
|
|
1000 |
Which Compression, Digressive or Eccentric Compression? |
2021-03-29 |
|
|
1001 |
Why are we divided on the Utility of Compression after Endo Venous Treatments? |
2021-03-29 |
|
|
1002 |
Myocardial Infarction and its causes |
2021-03-26 |
|
|
1003 |
Myocardial Infraction and its causes |
2021-03-25 |
|
|
1004 |
Risks |
2021-03-24 |
|
|
1005 |
Exercises |
2021-03-24 |
|
|
1006 |
Recovery |
2021-03-24 |
|
|
1007 |
Tools used in bioinformatics |
2021-03-15 |
|
|
1008 |
Presentation at meetings |
2021-03-12 |
|
|
1009 |
Report of a Case |
2021-03-12 |
|
|
1010 |
Conflicts of Interest / Competing Interests |
2021-03-12 |
|
|
1011 |
Editorial Highlights for Journal of Nursing Research and Practice |
2021-03-03 |
|
|
1012 |
Retrospective Study |
2021-02-04 |
|
|
1013 |
Societal Perspective |
2021-02-03 |
|
|
1014 |
Economic Recovery and Reopening: A Lego Modular Approach to the Unknown |
2021-02-03 |
|
|
1015 |
Multiplex Testing: a Must Have for Fall and Controlling a Second Wave |
2021-02-03 |
|
|
1016 |
The Role of the Public Health Response |
2021-02-03 |
|
|
1017 |
It Takes Two to Tango: How South Korea Refused to Dance with Covid-19 |
2021-02-03 |
|
|
1018 |
How Deep is the Economic Valley |
2021-02-03 |
|
|
1019 |
Further Improvements in Policies |
2021-01-29 |
|
|
1020 |
Impacts of the Policy on the Health of the Children |
2021-01-29 |
|
|
1021 |
Sugar Tax Policy for Children Health |
2021-01-29 |
|
|
1022 |
Policies to Cure Children Health |
2021-01-29 |
|
|
1023 |
Health Related Issues for Children |
2021-01-29 |
|
|
1024 |
Application of Nmc Code |
2021-01-29 |
|
|
1025 |
Conflicts of Interest and Informed Consent |
2021-01-28 |
|
|
1026 |
Case Report (3) |
2021-01-28 |
|
|
1027 |
Case Report (2) |
2021-01-28 |
|
|
1028 |
Relevance of the Study |
2021-01-22 |
|
|
1029 |
Response From WHO |
2021-01-22 |
|
|
1030 |
Impact |
2021-01-22 |
|
|
1031 |
Discussion and Management |
2021-01-12 |
|
|
1032 |
Clinical Manifestations |
2021-01-12 |
|
|
1033 |
Method of saliva collection |
2021-01-12 |
|
|
1034 |
Literature Search |
2021-01-11 |
|
|
1035 |
Vein Glue Allergy |
2020-12-28 |
|
|
1036 |
Exercise, Nutrition and Alcohol Reduction |
2020-12-24 |
|
|
1037 |
Practical Guidelines Developed by Practitioners to Improve the Health and Well-Being of Both Individuals |
2020-12-24 |
|
|
1038 |
Principles of Health and Fitness and the Issues and Agendas Concerning a Healthy Lifestyle |
2020-12-24 |
|
|
1039 |
Patient Assessment |
2020-12-18 |
|
|
1040 |
Experimental Results |
2020-12-16 |
|
|
1041 |
Limitations and Future Research |
2020-12-16 |
|
|
1042 |
Ophthalmology |
2020-12-15 |
|
|
1043 |
Occurrence of Glaucoma |
2020-12-15 |
|
|
1044 |
Testing of Drug |
2020-12-03 |
|
|
1045 |
Monitoring the Drug |
2020-12-03 |
|
|
1046 |
Significance of TDM |
2020-12-03 |
|
|
1047 |
Process of Drug Development |
2020-12-03 |
|
|
1048 |
Intuition of Pharmacovigilance |
2020-12-03 |
|
|
1049 |
Circulatory strain |
2020-12-03 |
|
|
1050 |
Sickle Cell Anemia |
2020-12-03 |
|
|
1051 |
Erectile dysfunction |
2020-12-03 |
|
|
1052 |
Prostate carcinoma |
2020-12-03 |
|
|
1053 |
Uterine Fibroids ndometriosis |
2020-12-03 |
|
|
1054 |
Polycystic Ovary Syndrome |
2020-12-03 |
|
|
1055 |
Aims |
2020-12-02 |
|
|
1056 |
Women Health Nursing |
2020-12-02 |
|
|
1057 |
Surgery Nursing |
2020-12-02 |
|
|
1058 |
Public Health Nursing |
2020-12-02 |
|
|
1059 |
Pediatric Nursing |
2020-12-02 |
|
|
1060 |
Oncology and Cancer Nursing |
2020-12-02 |
|
|
1061 |
Editorial on Nano Based Benefits in Agriculture |
2020-11-21 |
|
|
1062 |
Case Represntation |
2020-11-13 |
|
|
1063 |
Research Study |
2020-10-21 |
|
|
1064 |
Eligibility |
2020-10-16 |
|
|
1065 |
[Cognitive Psychotherapy2020] Young Scientist Awards |
2020-10-16 |
|
|
1066 |
Subject Advantages: |
2020-10-16 |
|
|
1067 |
Why should attend? |
2020-10-16 |
|
|
1068 |
Declaration of Competing Interest |
2020-09-09 |
|
|
1069 |
Recommendations and Sustainability Plan |
2020-09-09 |
|
|
1070 |
Lessons Learnt |
2020-09-09 |
|
|
1071 |
Methodology Overview |
2020-09-09 |
|
|
1072 |
Project Goals |
2020-09-09 |
|
|
1073 |
Case Series |
2020-09-07 |
|
|
1074 |
Contraception |
2020-08-31 |
|
|
1075 |
Reproductive Medicine |
2020-08-31 |
|
|
1076 |
Iron Deficiency Anemia |
2020-08-31 |
|
|
1077 |
Haemoglobin |
2020-08-31 |
|
|
1078 |
Haematology |
2020-08-31 |
|
|
1079 |
Signs and side effects |
2020-08-31 |
|
|
1080 |
Blood Pressure |
2020-08-31 |
|
|
1081 |
Retraction Note |
2020-08-29 |
|
|
1082 |
Clinical Case |
2020-08-21 |
|
|
1083 |
Patient and Methods |
2020-08-21 |
|
|
1084 |
Disclosure and Conflict of Interest |
2020-08-20 |
|
|
1085 |
Discussion and Review of Literature |
2020-08-20 |
|
|
1086 |
Pathomechanics |
2020-08-20 |
|
|
1087 |
Lever Sign Test |
2020-08-20 |
|
|
1088 |
Research Interest |
2020-08-19 |
|
|
1089 |
Social Media |
2020-08-19 |
|
|
1090 |
Insight of the Journal |
2020-08-19 |
|
|
1091 |
Journal Topics |
2020-08-19 |
|
|
1092 |
Role of Pharmacology of Covid 19 |
2020-08-19 |
|
|
1093 |
TO-NSTEMI |
2020-08-14 |
|
|
1094 |
Further Research |
2020-08-14 |
|
|
1095 |
Transport of Carbon dioxide to lungs |
2020-08-08 |
|
|
1096 |
Structure of haemoglobin |
2020-08-08 |
|
|
1097 |
Conclusion and Future Work |
2020-08-08 |
|
|
1098 |
Results and Validation |
2020-08-08 |
|
|
1099 |
Data Collection and Preprocessing |
2020-08-08 |
|
|
1100 |
Blood Cells |
2020-08-08 |
|
|
1101 |
Coagulation |
2020-08-08 |
|
|
1102 |
Whole Blood Cells |
2020-08-08 |
|
|
1103 |
Function of Blood |
2020-08-08 |
|
|
1104 |
Comparison and Discussion |
2020-08-08 |
|
|
1105 |
System Architecture |
2020-08-08 |
|
|
1106 |
Ambient Sensors and Wearables |
2020-08-08 |
|
|
1107 |
Expected Impact |
2020-08-08 |
|
|
1108 |
Results and Discussions |
2020-08-08 |
|
|
1109 |
Study Intervention |
2020-08-07 |
|
|
1110 |
Note |
2020-08-07 |
|
|
1111 |
Conclusion and Significance |
2020-08-07 |
|
|
1112 |
Conflict of Interest |
2020-08-06 |
|
|
1113 |
Compliance with Ethical Standards |
2020-08-06 |
|
|
1114 |
Ethical Responsibilities |
2020-08-05 |
|
|
1115 |
Level of Evidence |
2020-08-05 |
|
|
1116 |
Plastic Surgery Engagement And Future Directions |
2020-07-29 |
|
|
1117 |
Reconstructive Surgery Options |
2020-07-29 |
|
|
1118 |
Historical Management of FGM |
2020-07-29 |
|
|
1119 |
Our Discussion: Oxygen Therapy – Vascular and Further Indications |
2020-07-23 |
|
|
1120 |
Casuistic View |
2020-07-23 |
|
|
1121 |
Therapeutic View: Oxygen Therapy for Varicose Veins - Our Therapeutic Consequences |
2020-07-23 |
|
|
1122 |
Therapeutical View: Oxygen Therapy for Varicose Veins - What Can We Do? |
2020-07-23 |
|
|
1123 |
And Here Lies the Causative Pathological Connection to Leg Varices |
2020-07-23 |
|
|
1124 |
Pathophysiological View: Oxygen Therapy for Varicose Veins - The Pathology of Microcirculation in the Leg Capillaries |
2020-07-23 |
|
|
1125 |
Oxygen Therapy for Varicose Veins: Lack of Oxygen, Lack of Cell Energy |
2020-07-23 |
|
|
1126 |
Discussion-Quoted From the Guideline for Compression Therapy |
2020-07-23 |
|
|
1127 |
Results-Our First Experiences with Postoperative Massage Therapy |
2020-07-23 |
|
|
1128 |
Pathophysiological Considerations-Ipc after Varicose Vein Therapy |
2020-07-23 |
|
|
1129 |
Saphenion: Compression Massage after Vein Glue/Microfoam |
2020-07-23 |
|
|
1130 |
History-Massage of the Leg after Venaseal or Sealing Foam Therapy |
2020-07-23 |
|
|
1131 |
Thanks and Acknowledgments to Important Reviewers and Editors for Their Contribution |
2020-07-23 |
|
|
1132 |
Using Social Media/Digital Marketing to Showcase Articles Published in Your Journal |
2020-07-23 |
|
|
1133 |
Objectives of 2021 |
2020-07-23 |
|
|
1134 |
Highlights of 2019 |
2020-07-23 |
|
|
1135 |
About The Journal |
2020-07-23 |
|
|
1136 |
Editorial Content |
2020-07-22 |
|
|
1137 |
Editor’s Note |
2020-07-20 |
|
|
1138 |
Declaration of Patient Consent |
2020-07-10 |
|
|
1139 |
Interviews |
2020-07-09 |
|
|
1140 |
System Design |
2020-07-09 |
|
|
1141 |
Experiments |
2020-07-09 |
|
|
1142 |
Google Analytics |
2020-07-06 |
|
|
1143 |
Scope of the journal |
2020-07-06 |
|
|
1144 |
Research and Reviews |
2020-07-06 |
|
|
1145 |
Authors’ Note |
2020-07-03 |
|
|
1146 |
Authors’ Note |
2020-07-03 |
|
|
1147 |
Biography |
2020-07-01 |
|
|
1148 |
Treatment Options |
2020-06-02 |
|
|
1149 |
Editorial Note |
2020-06-02 |
|
|
1150 |
Rational of the Study |
2020-05-08 |
|
|
1151 |
Perception of Mental Health among Adolescents and Self Concept |
2020-05-08 |
|
|
1152 |
Anxiety and Depression among Adolescent |
2020-05-08 |
|
|
1153 |
Mental Health Problems among Adolescents |
2020-05-08 |
|
|
1154 |
Mechanical Postconditioning |
2020-03-19 |
|
|
1155 |
Thrombus Aspiration |
2020-03-19 |
|
|
1156 |
Pharmacological Treatment |
2020-03-19 |
|
|
1157 |
Risk Factors and Outcomes of No-Reflow |
2020-03-19 |
|
|
1158 |
Thematic Analysis |
2020-03-13 |
|
|
1159 |
Declarations of Interest |
2020-03-13 |
|
|
1160 |
Implications for Nursing Practice |
2020-03-03 |
|
|
1161 |
Effects of Intrascrotal Pressure on Testis |
2020-03-02 |
|
|
1162 |
Method of Data Collection and Analysis |
2020-03-02 |
|
|
1163 |
Global Market Value |
2020-02-28 |
|
|
1164 |
Targeted Audience |
2020-02-28 |
|
|
1165 |
Research Methods |
2020-02-17 |
|
|
1166 |
Funding Support |
2020-02-17 |
|
|
1167 |
Financial Disclosure |
2020-02-17 |
|
|
1168 |
Source of Founding |
2020-02-17 |
|
|
1169 |
Knee Function Postoperative Results |
2020-02-17 |
|
|
1170 |
Clinical Outcomes |
2020-02-17 |
|
|
1171 |
Awards 2020 |
2020-02-11 |
|
|
1172 |
2020 Conference Announcement |
2020-02-11 |
|
|
1173 |
Consent for Publication |
2020-02-10 |
|
|
1174 |
Best Organising Committee Member of Neuro Meet 2020 |
2020-02-10 |
|
|
1175 |
The 8th International Conference on Neuroscience and Neurological Disorders 2020 |
2020-02-10 |
|
|
1176 |
7th Annual meeting on Neurosurgery and Neurological surgeons |
2020-02-10 |
|
|
1177 |
Young Research Forum Announcement |
2020-02-05 |
|
|
1178 |
Literature Review – A Case Scenario |
2020-01-27 |
|
|
1179 |
Conference Opportunities: |
2020-01-24 |
|
|
1180 |
What’s New this year? |
2020-01-24 |
|
|
1181 |
Announcement |
2020-01-24 |
|
|
1182 |
Understudy Ambassador Award |
2020-01-24 |
|
|
1183 |
Youthful Research Award |
2020-01-24 |
|
|
1184 |
Professional Level (The Research commitment Award) |
2020-01-24 |
|
|
1185 |
Immunology Drug Market Segmentation |
2020-01-22 |
|
|
1186 |
Immunology Market Research will allow you to |
2020-01-22 |
|
|
1187 |
Infectious Diseases Diagnostics Market |
2020-01-22 |
|
|
1188 |
Tourist Attraction |
2020-01-22 |
|
|
1189 |
Criteria for The Best Poster Presentation Award |
2020-01-22 |
|
|
1190 |
The Best Poster Presentation Award |
2020-01-22 |
|
|
1191 |
Session’s Best Presentation Awards |
2020-01-22 |
|
|
1192 |
Criteria for the Best Student Presentation Award |
2020-01-22 |
|
|
1193 |
The Best Student Presentation Award |
2020-01-22 |
|
|
1194 |
Best Paper Award |
2020-01-22 |
|
|
1195 |
Best Poster Award Nursing 2020 |
2020-01-22 |
|
|
1196 |
Best Organising Committee Member Nursing Care 2020 |
2020-01-22 |
|
|
1197 |
Best Keynote Speaker Nursing Care 2020 |
2020-01-22 |
|
|
1198 |
Best Speaker Award for Nursing Care 2020 |
2020-01-22 |
|
|
1199 |
Major Nursing Universities in Asia Pacific |
2020-01-22 |
|
|
1200 |
Major Nursing Universities in Middle East |
2020-01-22 |
|
|
1201 |
Major Nursing Universities in Europe |
2020-01-22 |
|
|
1202 |
Major Nursing Universities in USA |
2020-01-22 |
|
|
1203 |
The subspecialty of Nursing Field includes |
2020-01-22 |
|
|
1204 |
Associations and Societies globally |
2020-01-22 |
|
|
1205 |
2020 Best Nursing Schools in World |
2020-01-22 |
|
|
1206 |
Development of Nursing Research in future |
2020-01-22 |
|
|
1207 |
Quick Look at the Revenue of Nursing Career |
2020-01-22 |
|
|
1208 |
Analysis and Aspects of Registered Nurses 2020 Conference |
2020-01-22 |
|
|
1209 |
Hospitals Worldwide |
2020-01-22 |
|
|
1210 |
Members Associated with Primary Healthcare |
2020-01-22 |
|
|
1211 |
Global Vocal Biomarkers Market: |
2020-01-21 |
|
|
1212 |
Best Organising Committee Member |
2020-01-21 |
|
|
1213 |
Worldwide Market on Pathology |
2020-01-21 |
|
|
1214 |
Significance and Scope |
2020-01-21 |
|
|
1215 |
3. Session’s Best Presentation Award: |
2020-01-21 |
|
|
1216 |
2. Best Poster Award: |
2020-01-21 |
|
|
1217 |
1. Young Scientist Award: |
2020-01-21 |
|
|
1218 |
Student Ambassador Award |
2020-01-21 |
|
|
1219 |
Keynote Speaker Memento |
2020-01-21 |
|
|
1220 |
Young Research Award |
2020-01-21 |
|
|
1221 |
Conference Opportunities |
2020-01-21 |
|
|
1222 |
About the Venue |
2020-01-21 |
|
|
1223 |
Scope of Gynecology and Obstetrics |
2020-01-21 |
|
|
1224 |
Research Excellence Awards |
2020-01-21 |
|
|
1225 |
Pathogenesis And Risk Factors |
2020-01-20 |
|
|
1226 |
Further Key Findings from the Report Suggest: |
2020-01-17 |
|
|
1227 |
Award recognizes Masters / Ph. D./Post Ph.D |
2020-01-17 |
|
|
1228 |
Excellence Award |
2020-01-17 |
|
|
1229 |
Out Standing Award |
2020-01-17 |
|
|
1230 |
Participant Details |
2020-01-17 |
|
|
1231 |
Dubai: The City Above Sky |
2020-01-17 |
|
|
1232 |
Program Structure |
2020-01-17 |
|
|
1233 |
Track Structure |
2020-01-17 |
|
|
1234 |
Notable Speakers of Psychiatry 2019 |
2020-01-17 |
|
|
1235 |
Past Conference Report |
2020-01-17 |
|
|
1236 |
Benefits for Young Scientist Forum: |
2020-01-17 |
|
|
1237 |
Poster presentation Benefits: |
2020-01-17 |
|
|
1238 |
Best Poster Award: |
2020-01-17 |
|
|
1239 |
Awards: |
2020-01-17 |
|
|
1240 |
Market Analysis: Polymers |
2020-01-16 |
|
|
1241 |
Smart Polymer Market Size and Trend |
2020-01-16 |
|
|
1242 |
Market Value on Nursing |
2020-01-16 |
|
|
1243 |
Comparison of laparoscopy vs. Robotics in rectal cancer |
2020-01-13 |
|
|
1244 |
Backgorund |
2020-01-13 |
|
|
1245 |
Ethical Approval and Consent to Participate |
2020-01-10 |
|
|
1246 |
Statistical Methods |
2020-01-09 |
|
|
1247 |
Neuroimmunology 2018 Gallery: |
2020-01-08 |
|
|
1248 |
Market Sectors |
2020-01-08 |
|
|
1249 |
Prevalence of Neurological Disorders |
2020-01-08 |
|
|
1250 |
Universities and Colleges: |
2019-12-31 |
|
|
1251 |
Why Singapore? |
2019-12-31 |
|
|
1252 |
Need of Neurosurgery: |
2019-12-31 |
|
|
1253 |
Best Student Presentation Award |
2019-12-30 |
|
|
1254 |
Best Speaker Presentation Award |
2019-12-30 |
|
|
1255 |
Best Organising Commitee Member |
2019-12-30 |
|
|
1256 |
Best Keynote Speaker Presentation Award |
2019-12-30 |
|
|
1257 |
The City |
2019-12-19 |
|
|
1258 |
Why to Attend? |
2019-12-19 |
|
|
1259 |
Why Frankfurt? |
2019-12-19 |
|
|
1260 |
Highlights For Smart Materials Conference |
2019-12-19 |
|
|
1261 |
Market Analysis Of Laboratory Medicine |
2019-12-19 |
|
|
1262 |
Overall Statistics |
2019-12-19 |
|
|
1263 |
Best Poster Presentation Award |
2019-12-19 |
|
|
1264 |
Best Young Research Forum Award |
2019-12-19 |
|
|
1265 |
Best Plenary Award |
2019-12-19 |
|
|
1266 |
Best Keynote Award |
2019-12-19 |
|
|
1267 |
Best Organizing Committee Member Award |
2019-12-19 |
|
|
1268 |
Scholar/ Student Level |
2019-12-19 |
|
|
1269 |
Market Growth of Neuroscience |
2019-12-19 |
|
|
1270 |
Exceptional Masters/Ph.d./Post Doctorate Proposition Work Presentation in Cancer Science 2020 |
2019-12-18 |
|
|
1271 |
Best Poster Presentation in Cancer Science 2020 |
2019-12-18 |
|
|
1272 |
Best Keynote Speaker in Cancer Science 2020 |
2019-12-18 |
|
|
1273 |
The Exceptional Speaker in Cancer Science 2020 |
2019-12-18 |
|
|
1274 |
Researcher Level (The Upcoming Researcher Award) |
2019-12-18 |
|
|
1275 |
Proficient Level (The Research Contribution Award) |
2019-12-18 |
|
|
1276 |
Master Level (Scientific Service Achievement Award) |
2019-12-18 |
|
|
1277 |
Medical Robotics and Computer Assisted Surgery Market Overview: |
2019-12-18 |
|
|
1278 |
Why Japan? |
2019-12-18 |
|
|
1279 |
Importance |
2019-12-18 |
|
|
1280 |
Best Poster Award: Breast Cancer |
2019-12-17 |
|
|
1281 |
Categories of the Awards Section are as Follows |
2019-12-17 |
|
|
1282 |
Notable Speakers of Cancer Research 2019 |
2019-12-17 |
|
|
1283 |
Eminent Organizing Committee Members of Cancer Research 2019 |
2019-12-17 |
|
|
1284 |
Overall Statistics |
2019-12-17 |
|
|
1285 |
Statistics Of Industries Associated With Proteomics |
2019-12-17 |
|
|
1286 |
Best Keynote Speaker |
2019-12-17 |
|
|
1287 |
Our Conference Highlights Includes |
2019-12-17 |
|
|
1288 |
Key Market Trends |
2019-12-17 |
|
|
1289 |
Market Analysis |
2019-12-17 |
|
|
1290 |
Notable Speakers of Cancer Science 2019 |
2019-12-17 |
|
|
1291 |
Young Researchers Forum (Yrf) |
2019-12-17 |
|
|
1292 |
Poster Presentation |
2019-12-13 |
|
|
1293 |
Video Presentation |
2019-12-13 |
|
|
1294 |
Young Research Forum |
2019-12-13 |
|
|
1295 |
Delegate Award |
2019-12-13 |
|
|
1296 |
Speaker Awards |
2019-12-13 |
|
|
1297 |
Keynote Speaker Awards |
2019-12-13 |
|
|
1298 |
Awards |
2019-12-13 |
|
|
1299 |
Medicinal Chemistry 2020 |
2019-12-13 |
|
|
1300 |
Scope and Importance |
2019-12-13 |
|
|
1301 |
Why Tokyo? |
2019-12-13 |
|
|
1302 |
Benefits For Young Scientists |
2019-12-13 |
|
|
1303 |
Poster presentation Benefits: |
2019-12-13 |
|
|
1304 |
YOUNG SCIENTIST RESEARCHER (YRF) |
2019-12-13 |
|
|
1305 |
Benefits of Attending Physicians 2020 |
2019-12-13 |
|
|
1306 |
SAVE THE DATE for Physicians 2020!!! |
2019-12-13 |
|
|
1307 |
Embryological Significance |
2019-12-11 |
|
|
1308 |
Top companies in Italy |
2019-12-11 |
|
|
1309 |
Top companies around the globe |
2019-12-11 |
|
|
1310 |
Top Universities around the globe |
2019-12-11 |
|
|
1311 |
Target Audience |
2019-12-11 |
|
|
1312 |
Major Neurology and Neurophysiology Associations around the Globe |
2019-12-11 |
|
|
1313 |
Glance at Market Share |
2019-12-11 |
|
|
1314 |
Importance and Scope |
2019-12-11 |
|
|
1315 |
Best Session of the Day |
2019-12-10 |
|
|
1316 |
Best Poster Presentation |
2019-12-10 |
|
|
1317 |
Best Keynote Presentation |
2019-12-10 |
|
|
1318 |
Best Speaker Presentation |
2019-12-10 |
|
|
1319 |
Young Scientist |
2019-12-10 |
|
|
1320 |
Women Scientist |
2019-12-10 |
|
|
1321 |
Scholar/Student Level |
2019-12-10 |
|
|
1322 |
High-Profile/Expert Level |
2019-12-10 |
|
|
1323 |
Veteran Level |
2019-12-10 |
|
|
1324 |
Be one among the aspirants of Advanced Neurology 2020! |
2019-12-10 |
|
|
1325 |
Young Scientist Award |
2019-12-10 |
|
|
1326 |
Best Poster Award |
2019-12-10 |
|
|
1327 |
Young Research Forum Research Award |
2019-12-10 |
|
|
1328 |
Outstanding Poster Award for Excellence |
2019-12-10 |
|
|
1329 |
Best Organizing Committee Member Award for Excellence |
2019-12-10 |
|
|
1330 |
Outstanding Speaker Award for Excellence |
2019-12-10 |
|
|
1331 |
Best Keynote Speaker Awards for Excellence |
2019-12-10 |
|
|
1332 |
Materials Need for Participation |
2019-12-10 |
|
|
1333 |
Benefits |
2019-12-10 |
|
|
1334 |
Nairs Classification |
2019-12-09 |
|
|
1335 |
Selection of Cases |
2019-12-09 |
|
|
1336 |
Data and Methodology |
2019-12-09 |
|
|
1337 |
Funding source |
2019-11-07 |
|
|
1338 |
Funding Sources/Disclosures |
2019-10-31 |
|
|
1339 |
Other Biomedical Named Entity Recognition and Normalization |
2019-10-31 |
|
|
1340 |
Gene Normalization |
2019-10-31 |
|
|
1341 |
Gene Mention Recognition |
2019-10-31 |
|
|
1342 |
Appendix |
2019-10-31 |
|
|
1343 |
Consent to Publish |
2019-09-19 |
|
|
1344 |
Consent to Participate |
2019-09-19 |
|
|
1345 |
Case Destion |
2019-09-06 |
|
|
1346 |
Disclamier |
2019-09-05 |
|
|
1347 |
Settings and Design |
2019-09-03 |
|
|
1348 |
Context |
2019-09-03 |
|
|
1349 |
Case Description |
2019-09-02 |
|
|
1350 |
Authors' Contributions |
2019-09-02 |
|
|
1351 |
Authors’ Contributions |
2019-09-02 |
|
|
1352 |
Treatment Implications |
2019-08-28 |
|
|
1353 |
Mechanisms of Action |
2019-08-28 |
|
|
1354 |
Strengths and Weaknesses |
2019-08-26 |
|
|
1355 |
Disclaimer |
2019-08-26 |
|
|
1356 |
Thyroid Hormone |
2019-08-26 |
|
|
1357 |
Statistic Analysis |
2019-08-26 |
|
|
1358 |
Most Common Cardiovascular Risk Factors |
2019-08-26 |
|
|
1359 |
Limitations of the Present Study |
2019-08-03 |
|
|
1360 |
Acronyms and Abbreviations |
2019-07-29 |
|
|
1361 |
WayForward |
2019-07-24 |
|
|
1362 |
Conflict of Interests |
2019-07-18 |
|
|
1363 |
Advantages Of Natural Nail |
2019-07-18 |
|
|
1364 |
Exclusion criteria |
2019-07-18 |
|
|
1365 |
Inclusion Criteria |
2019-07-18 |
|
|
1366 |
Surgical Procedure |
2019-07-05 |
|
|
1367 |
Case Report |
2019-07-05 |
|
|
1368 |
Tubal Infertility |
2019-07-04 |
|
|
1369 |
Male Factor Infertility |
2019-07-04 |
|
|
1370 |
Endometriosis |
2019-07-04 |
|
|
1371 |
Unexplained Infertility |
2019-07-04 |
|
|
1372 |
Case Scenario |
2019-06-27 |
|
|
1373 |
heading |
2019-06-12 |
|
|
1374 |
Results and Conclusions |
2019-06-10 |
|
|
1375 |
Role Of Ranolazine |
2019-06-10 |
|
|
1376 |
Traditional Treatments For NHL |
2019-06-07 |
|
|
1377 |
Traditional Treatments For Nhl< |
2019-06-07 |
|
|
1378 |
NHL Origiates in gremiaERMINAL CENTERS |
2019-06-07 |
|
|
1379 |
Future Research Prospects |
2019-06-07 |
|
|
1380 |
Etiopathogenesis |
2019-06-07 |
|
|
1381 |
Subject And Methods |
2019-05-27 |
|
|
1382 |
Patients |
2019-05-27 |
|
|
1383 |
Epidemiology and Clinical Presentation |
2019-05-24 |
|
|
1384 |
Roshan Noor Mohamed |
2019-05-24 |
|
|
1385 |
O.A.R.S |
2019-05-24 |
|
|
1386 |
Elicit Change Talk |
2019-05-24 |
|
|
1387 |
Principles of MI |
2019-05-24 |
|
|
1388 |
Spirit of MI |
2019-05-24 |
|
|
1389 |
Elements of Motivational Interviewing |
2019-05-24 |
|
|
1390 |
What is MI? |
2019-05-24 |
|
|
1391 |
Literature Review in Relation to Dentistry |
2019-05-24 |
|
|
1392 |
Ethics Approval and Consent to Participate |
2019-05-24 |
|
|
1393 |
Interventions |
2019-05-24 |
|
|
1394 |
Local Hemostatic Agents |
2019-05-15 |
|
|
1395 |
Surgical Treatment |
2019-05-15 |
|
|
1396 |
Local Anesthesia |
2019-05-15 |
|
|
1397 |
Potential Food Applications |
2019-05-14 |
|
|
1398 |
Properties of Biosurfactants |
2019-05-14 |
|
|
1399 |
Final Diagnosis |
2019-05-08 |
|
|
1400 |
Conclusions and Future work |
2019-05-02 |
|
|
1401 |
Case Study for Design Principles for Open eHealth Platform |
2019-05-02 |
|
|
1402 |
National eHealth in Slovenia |
2019-05-02 |
|
|
1403 |
Disclosures/Conflicts of Interests |
2019-05-02 |
|
|
1404 |
Descriptions Of The Everyday Reality Through Case Examples |
2019-05-02 |
|
|
1405 |
Questionnaire Design and Sampling |
2019-05-02 |
|
|
1406 |
Theoretical Framework |
2019-05-02 |
|
|
1407 |
Multi-feature Service for Smoking Cessation |
2019-05-02 |
|
|
1408 |
Appendix III: Summary of Studies |
2019-05-02 |
|
|
1409 |
Appendix II: Conceptual Map |
2019-05-02 |
|
|
1410 |
Appendix I: Search Terms |
2019-05-02 |
|
|
1411 |
Author Contributions |
2019-05-02 |
|
|
1412 |
Author's Contributions |
2019-05-01 |
|
|
1413 |
Immunological Evaluation |
2019-05-01 |
|
|
1414 |
Question |
2019-04-26 |
|
|
1415 |
Operative Procedure |
2019-04-16 |
|
|
1416 |
Value Of Pre-Operative Planning To The Surgeon And Trainee |
2019-04-16 |
|
|
1417 |
Third Step |
2019-04-16 |
|
|
1418 |
Second Step |
2019-04-16 |
|
|
1419 |
Medications |
2019-04-16 |
|
|
1420 |
First Step |
2019-04-16 |
|
|
1421 |
Some Facts About Kuwait And The Prevalence Of Knee OA |
2019-04-16 |
|
|
1422 |
Declaration of Interest |
2019-04-15 |
|
|
1423 |
Purpose |
2019-04-15 |
|
|
1424 |
Classification of Renal Vein Anomalies |
2019-04-15 |
|
|
1425 |
Embryogenesis of left retro-aortic renal vein Draining into left common iliac vein anomaly |
2019-04-15 |
|
|
1426 |
Statistical Analyses |
2019-03-29 |
|
|
1427 |
The H@H Project Infrastructure |
2019-03-20 |
|
|
1428 |
Example for Re-Engineering an ISO Specification Using the Interoperability Reference Architecture Model |
2019-03-20 |
|
|
1429 |
The Interoperability Reference Architecture Model Standard |
2019-03-20 |
|
|
1430 |
The Transformative Healthcare Interoperability Challenge |
2019-03-20 |
|
|
1431 |
The Transformation of the Healthcare Eco-System – A System-Theoretical Approach |
2019-03-20 |
|
|
1432 |
Better Health |
2019-03-20 |
|
|
1433 |
Evolving Standards |
2019-03-20 |
|
|
1434 |
The World as it is |
2019-03-20 |
|
|
1435 |
What these Changes Mean to Better Health |
2019-03-20 |
|
|
1436 |
A Changing World |
2019-03-20 |
|
|
1437 |
Related Works |
2019-03-19 |
|
|
1438 |
Clinical Applications of Diode Lasers |
2019-03-19 |
|
|
1439 |
Declaration of Interests |
2019-03-19 |
|
|
1440 |
Paper Context |
2019-03-19 |
|
|
1441 |
Funding Information |
2019-03-19 |
|
|
1442 |
Ethics and Consent |
2019-03-19 |
|
|
1443 |
The Data |
2019-03-19 |
|
|
1444 |
The Model |
2019-03-19 |
|
|
1445 |
Human Subjects and Method |
2019-03-19 |
|
|
1446 |
New Waves |
2019-03-19 |
|
|
1447 |
Satellite Communication of Homecare Systems Showed Needs of ASP |
2019-03-19 |
|
|
1448 |
The Introduction of Cloud Technology in EPR and PACS Sharing System |
2019-03-19 |
|
|
1449 |
Thin-client System |
2019-03-19 |
|
|
1450 |
Standardization |
2019-03-19 |
|
|
1451 |
Abbreviations and Acronyms Used |
2019-03-19 |
|
|
1452 |
International Interoperability |
2019-03-18 |
|
|
1453 |
Private and Security Interoperability |
2019-03-18 |
|
|
1454 |
Bussiness Interoperability |
2019-03-18 |
|
|
1455 |
Consumer Interoperability |
2019-03-18 |
|
|
1456 |
Stackholder Interoperability |
2019-03-18 |
|
|
1457 |
Functional Interoperability |
2019-03-18 |
|
|
1458 |
Semantic Interoperability |
2019-03-18 |
|
|
1459 |
Definitions of Interoperability |
2019-03-18 |
|
|
1460 |
Complementary Treatments |
2019-03-14 |
|
|
1461 |
Psychopharmacotherapy For Alzheimer Disease And Other Dementia |
2019-03-14 |
|
|
1462 |
Dementia Variations With Age of Occurence |
2019-03-14 |
|
|
1463 |
On Neurodegenerative Dementia |
2019-03-14 |
|
|
1464 |
On Cognitive Impairment |
2019-03-14 |
|
|
1465 |
Contributing Diseases |
2019-03-14 |
|
|
1466 |
Approach To Diagnosis |
2019-03-14 |
|
|
1467 |
Mental Disorder Classification |
2019-03-14 |
|
|
1468 |
Staging Of The Disease |
2019-03-14 |
|
|
1469 |
Signs and Symptoms |
2019-03-14 |
|
|
1470 |
Epidemiology of the Disease |
2019-03-14 |
|
|
1471 |
A Brief History |
2019-03-14 |
|
|
1472 |
Modeling Health Systems |
2019-03-08 |
|
|
1473 |
Contemporary Developments and Reflections on Professor Zvárová’s Fields of Interest |
2019-03-08 |
|
|
1474 |
Digital Health Directions |
2019-03-08 |
|
|
1475 |
Last Conversations |
2019-03-08 |
|
|
1476 |
Summary and Conclusion |
2019-03-08 |
|
|
1477 |
Future of Health Informatics – Major Issues Raised by Professional Women |
2019-03-08 |
|
|
1478 |
Perspectives for Future Development of Medical Informatics |
2019-03-08 |
|
|
1479 |
Medical Informatics Education Today |
2019-03-08 |
|
|
1480 |
Medical Informatics Curricula (Example of Bosnia and Herzegovina) |
2019-03-08 |
|
|
1481 |
The Bologna Process and Medical Informatics |
2019-03-08 |
|
|
1482 |
Medical Informatics – Educational Concepts |
2019-03-08 |
|
|
1483 |
Present and Future of Decision Support |
2019-03-08 |
|
|
1484 |
Data, Information and Knowledge |
2019-03-08 |
|
|
1485 |
In What Aspect is the Proposed Solution Actually Innovative? |
2019-03-08 |
|
|
1486 |
What Changes are Expected Due to the Project? |
2019-03-08 |
|
|
1487 |
What is the Goal of the Project? |
2019-03-08 |
|
|
1488 |
Problem Description |
2019-03-08 |
|
|
1489 |
Cadaveric Case Presentation |
2019-03-07 |
|
|
1490 |
Hypothesis Testing |
2019-03-07 |
|
|
1491 |
Partial Least Squares |
2019-03-07 |
|
|
1492 |
Variable Selection based on Maximal Conditional Entropy |
2019-03-07 |
|
|
1493 |
Principal Component Analysis |
2019-03-07 |
|
|
1494 |
Overview of Complexity Reduction |
2019-03-07 |
|
|
1495 |
Big Data in Biomedicine |
2019-03-07 |
|
|
1496 |
Patient Portals and Patient Empowerment |
2019-03-07 |
|
|
1497 |
From eHealth to ePatient |
2019-03-07 |
|
|
1498 |
EHR Systems Standards and Solutions |
2019-03-07 |
|
|
1499 |
EHR Systems‘ Interoperability |
2019-03-07 |
|
|
1500 |
EHR Systems’ Objectives and Requirements |
2019-03-07 |
|
|
1501 |
Conclusion and Final Considerations |
2019-03-07 |
|
|
1502 |
Clinical Outcomes of Ondansetron Administration with Elective Cesarean Delivery |
2019-03-07 |
|
|
1503 |
Photo Gallery |
2019-03-02 |
|
|
1504 |
Personality of Jana Zvárová |
2019-03-02 |
|
|
1505 |
Recognition of the Professional Prestige of Jana Zvárová |
2019-03-02 |
|
|
1506 |
Full Affirmation Period |
2019-03-02 |
|
|
1507 |
Ascension Period |
2019-03-02 |
|
|
1508 |
Early Work: Studies and Scientific Pursuits |
2019-03-02 |
|
|
1509 |
Human Subjects Protections |
2019-02-28 |
|
|
1510 |
Clinical Relevance Statement |
2019-02-28 |
|
|
1511 |
Limitations of Study |
2019-02-23 |
|
|
1512 |
Vibrational Oct Measurements |
2019-02-22 |
|
|
1513 |
Competing of Interests |
2019-02-11 |
|
|
1514 |
Risk Factors and Management |
2019-01-29 |
|
|
1515 |
How should evaluation start? |
2019-01-29 |
|
|
1516 |
Surgical Technique |
2019-01-28 |
|
|
1517 |
Contribution of the Authors |
2019-01-25 |
|
|
1518 |
Case Presentation and Observations |
2019-01-25 |
|
|
1519 |
Role Of Eosinophils In Cancer |
2019-01-23 |
|
|
1520 |
Eosinophils At Tumor Site |
2019-01-23 |
|
|
1521 |
MBL Other Than CLL-LIKE |
2019-01-22 |
|
|
1522 |
CLL-LIKE MBL |
2019-01-22 |
|
|
1523 |
Contemporary Therapeutic Agent |
2019-01-22 |
|
|
1524 |
Therapeutic Protocols |
2019-01-22 |
|
|
1525 |
Prognostic Determinants |
2019-01-22 |
|
|
1526 |
Radiological Investigations |
2019-01-22 |
|
|
1527 |
Genetic Modifications |
2019-01-22 |
|
|
1528 |
Comparison And Contrast |
2019-01-22 |
|
|
1529 |
Creative Inquiry Movements |
2019-01-22 |
|
|
1530 |
Activity Theory |
2019-01-22 |
|
|
1531 |
Construction Theory |
2019-01-22 |
|
|
1532 |
Immune Phenotypes In Lymphoblastic Lymphoma |
2019-01-22 |
|
|
1533 |
Tumour Morphology |
2019-01-22 |
|
|
1534 |
Disease Characterization |
2019-01-22 |
|
|
1535 |
Epidemiological view of colistin resistance in Faisalaabad, pakistan |
2019-01-12 |
|
|
1536 |
Plasmid-Mediated Colistin Resistance |
2019-01-12 |
|
|
1537 |
Colistin |
2019-01-12 |
|
|
1538 |
Antimicrobial Resistance (Amr) |
2019-01-12 |
|
|
1539 |
Suggestions |
2019-01-11 |
|
|
1540 |
Author’s Contributions |
2019-01-11 |
|
|
1541 |
Quality of Incision |
2019-01-11 |
|
|
1542 |
Histological Analysis |
2019-01-11 |
|
|
1543 |
Diffuse Oral Mucosal Pigmentation |
2019-01-11 |
|
|
1544 |
Causes of Melanocytic Pigmentation |
2019-01-11 |
|
|
1545 |
Reactive Melanocytic Pigmentation |
2019-01-11 |
|
|
1546 |
Disclosure of Interest |
2019-01-11 |
|
|
1547 |
Case Study-4 |
2019-01-11 |
|
|
1548 |
Ua/Nstemi |
2019-01-11 |
|
|
1549 |
Stemi |
2019-01-11 |
|
|
1550 |
Oxalate-Degrading Bacteria as new Therapeutic Tools for Preventing Kidney Stones |
2019-01-11 |
|
|
1551 |
Therapeutic Options and Methods of Prohibition of Kidney Stones |
2019-01-11 |
|
|
1552 |
Mechanism of Kidney Stone Formation |
2019-01-11 |
|
|
1553 |
Case Study-3 |
2019-01-10 |
|
|
1554 |
Case Study-2 |
2019-01-10 |
|
|
1555 |
Case Study-1 |
2019-01-10 |
|
|
1556 |
Methods and Strategies for Sand Search |
2019-01-10 |
|
|
1557 |
Regional Geology and Site Description |
2019-01-10 |
|
|
1558 |
Eestimation of Mineral Resources and Mineral Reserves |
2019-01-10 |
|
|
1559 |
Planning and Performing of Mineral Projects |
2019-01-10 |
|
|
1560 |
Therapeutic Intervention |
2019-01-10 |
|
|
1561 |
Prognostic Guide |
2019-01-10 |
|
|
1562 |
Radiographic Assay |
2019-01-10 |
|
|
1563 |
Immune Histochemistry |
2019-01-10 |
|
|
1564 |
Variants of Myoepithelioma |
2019-01-10 |
|
|
1565 |
Microscopy |
2019-01-10 |
|
|
1566 |
Naked Eye Inspection |
2019-01-10 |
|
|
1567 |
Histogenesis |
2019-01-10 |
|
|
1568 |
Disease Characteristics |
2019-01-10 |
|
|
1569 |
Rethinking Vaccine Design |
2019-01-10 |
|
|
1570 |
Pyrexias of Unknown Origin |
2019-01-10 |
|
|
1571 |
Zoonotic Transmission? |
2019-01-10 |
|
|
1572 |
Cross-Reactivity with ZIKA |
2019-01-10 |
|
|
1573 |
A New Dengue Serotype |
2019-01-10 |
|
|
1574 |
Lack of Specific Therapy |
2019-01-10 |
|
|
1575 |
Dengue Infection |
2019-01-10 |
|
|
1576 |
Dengue Virus |
2019-01-10 |
|
|
1577 |
List of Abbreviations |
2019-01-08 |
|
|
1578 |
Perspective |
2019-01-07 |
|
|
1579 |
Aim and Objectives |
2019-01-07 |
|
|
1580 |
Variation in Ear Shape |
2019-01-07 |
|
|
1581 |
Frankfort Horizontal |
2019-01-07 |
|
|
1582 |
Anatomical Landmarks of the Ear |
2019-01-07 |
|
|
1583 |
Anatomy of the External Ear |
2019-01-07 |
|
|
1584 |
Methods and Materials |
2019-01-07 |
|
|
1585 |
Declaration Of Interest |
2018-12-19 |
|
|
1586 |
Quantification Analysis For Total Alkaloids |
2018-12-17 |
|
|
1587 |
Aim of the Work |
2018-12-14 |
|
|
1588 |
Study Limitation |
2018-12-14 |
|
|
1589 |
Statistics |
2018-12-03 |
|
|
1590 |
Electrolyte-Layer Free Fuel Cell |
2018-11-24 |
|
|
1591 |
Conventional Solid Oxide Fuel Cell |
2018-11-24 |
|
|
1592 |
Outline of Experiment |
2018-11-24 |
|
|
1593 |
Critical Reynolds Number Values, Poiseuille Number and Ducts Cross-Section Curvature |
2018-11-24 |
|
|
1594 |
Experimental Friction Curves in Ducts of Complex Cross-Section Shape |
2018-11-24 |
|
|
1595 |
Key Messages |
2018-11-16 |
|
|
1596 |
Methodolgy |
2018-11-16 |
|
|
1597 |
Limits of the Study |
2018-11-16 |
|
|
1598 |
Data-Gathering Tools |
2018-11-16 |
|
|
1599 |
Acknowledgments |
2018-11-15 |
|
|
1600 |
Data Availability |
2018-11-12 |
|
|
1601 |
Consent to Participate and Publish |
2018-11-05 |
|
|
1602 |
Funding Statement |
2018-11-05 |
|
|
1603 |
Acknowledgment |
2018-11-05 |
|
|
1604 |
Limitation of the Study |
2018-11-05 |
|
|
1605 |
Limitations and Suggestion |
2018-11-05 |
|
|
1606 |
Literature Review and Discussion |
2018-11-05 |
|
|
1607 |
Introduction and Background |
2018-11-05 |
|
|
1608 |
What Dose Paper Adds? |
2018-10-30 |
|
|
1609 |
PCB Congener Profile and Homologues in Galatea Paradoxa from Ada in Ghana |
2018-10-25 |
|
|
1610 |
Risk Assessment of PCBs in Galatea paradoxa from Ada in Ghana and Health Implications on Consumers |
2018-10-25 |
|
|
1611 |
Effects Of Exercise On Protein Synthesis |
2018-10-17 |
|
|
1612 |
Phosphatidic Acid, Protein Synthesis From Resistance Training |
2018-10-17 |
|
|
1613 |
Leucine Protein Synthesis And Insulin Release |
2018-10-17 |
|
|
1614 |
Results and Observation |
2018-10-05 |
|
|
1615 |
Hazard Index (HI) of Pcbs in Galatea paradoxa from Ada in Ghana |
2018-09-27 |
|
|
1616 |
Toxicity Equivalents (TEQs) Concentration of PCB 118 |
2018-09-27 |
|
|
1617 |
Study Results in the Context of Published Studies |
2018-09-27 |
|
|
1618 |
PCB Congener Profile and Homologues in Galatea Paradoxa from Ada in Ghana |
2018-09-27 |
|
|
1619 |
Distribution Pattern of Pcb Congeners in Galatea paradoxa from Ada in Ghana During the Wet and Dry Seasons |
2018-09-27 |
|
|
1620 |
Procedure Used to Determine Hazard Index (Hi) and Toxic Equivalents (TEQs) of the Samples |
2018-09-27 |
|
|
1621 |
Computation of Recovery and Precision Estimation of Samples |
2018-09-27 |
|
|
1622 |
Quality Assurance |
2018-09-27 |
|
|
1623 |
Sample Collection and Processing |
2018-09-27 |
|
|
1624 |
Disclosure Statement |
2018-09-25 |
|
|
1625 |
Future Aspects of Crispr-Cas9 Technology |
2018-09-21 |
|
|
1626 |
Applications for Crispr-Cas9 Technology |
2018-09-21 |
|
|
1627 |
Mechanism |
2018-09-21 |
|
|
1628 |
How Was Crispr-Cas9 Developed? |
2018-09-21 |
|
|
1629 |
Who Invented Crispr-Cas9? |
2018-09-21 |
|
|
1630 |
CRISPR-cas9 |
2018-09-21 |
|
|
1631 |
TALENs |
2018-09-21 |
|
|
1632 |
ZFNs |
2018-09-21 |
|
|
1633 |
New Tools In DNA Editing |
2018-09-21 |
|
|
1634 |
The Story Of DNA Manipulation |
2018-09-21 |
|
|
1635 |
The Human Genome Project |
2018-09-21 |
|
|
1636 |
DNA: The Master Molecule |
2018-09-21 |
|
|
1637 |
History |
2018-09-21 |
|
|
1638 |
Case Details |
2018-09-21 |
|
|
1639 |
Net Trend |
2018-09-21 |
|
|
1640 |
Controversies and Variations in Practice |
2018-09-21 |
|
|
1641 |
Risks and Complications |
2018-09-21 |
|
|
1642 |
Indications |
2018-09-21 |
|
|
1643 |
Historical Perspective |
2018-09-21 |
|
|
1644 |
Experimental Details |
2018-09-21 |
|
|
1645 |
Nursing Implications |
2018-09-18 |
|
|
1646 |
EPS Analysis |
2018-09-11 |
|
|
1647 |
Microphytobenthos Observations |
2018-09-11 |
|
|
1648 |
Laboratory Analysis |
2018-09-11 |
|
|
1649 |
Study Period |
2018-09-06 |
|
|
1650 |
Humphrey |
2018-08-23 |
|
|
1651 |
Core Tip |
2018-08-22 |
|
|
1652 |
Prediction |
2018-08-22 |
|
|
1653 |
Risk Factors |
2018-08-22 |
|
|
1654 |
Ethics Approval |
2018-08-10 |
|
|
1655 |
Conflict Of Interest Disclosure |
2018-07-17 |
|
|
1656 |
Previous Presentations |
2018-07-13 |
|
|
1657 |
Research Methodology |
2018-07-13 |
|
|
1658 |
Limitation of study |
2018-07-13 |
|
|
1659 |
Materials and Method |
2018-07-11 |
|
|
1660 |
Material |
2018-07-11 |
|
|
1661 |
Aims & Objective |
2018-07-11 |
|
|
1662 |
Future of DE |
2018-07-06 |
|
|
1663 |
Electricity Generator Using DE |
2018-07-06 |
|
|
1664 |
Development of DE Actuators |
2018-07-06 |
|
|
1665 |
DE Summary and Operating Principle |
2018-07-06 |
|
|
1666 |
Results and Observations |
2018-07-02 |
|
|
1667 |
Conflict of Interest and Source of Funding |
2018-06-26 |
|
|
1668 |
Laboratory |
2018-06-26 |
|
|
1669 |
Conclusion And Perspectives |
2018-06-25 |
|
|
1670 |
Study On The Interactions Between Rimonabant And Cb1 Receptor By Means Of Molecular Modeling |
2018-06-25 |
|
|
1671 |
Relationship Between Structure and Activity Of Rimonbant and Taranabant |
2018-06-25 |
|
|
1672 |
ENDOCANNABINOID SYSTEM AND EATING ATTITUDES |
2018-06-25 |
|
|
1673 |
Types of cannabinoid receptors |
2018-06-25 |
|
|
1674 |
ENDOGENOUS CANNABINOIDS |
2018-06-25 |
|
|
1675 |
ENDOCANNABINOID SYSTEM (ECS) |
2018-06-25 |
|
|
1676 |
Surgical Treatment |
2018-06-05 |
|
|
1677 |
First-Time Dislocation |
2018-06-05 |
|
|
1678 |
Nonoperative Treatment |
2018-06-05 |
|
|
1679 |
Outcome Measurement System |
2018-06-05 |
|
|
1680 |
Pathoanatomy of Atraumatic Instability |
2018-06-05 |
|
|
1681 |
Pathoanatomy of Traumatic Posterior Instability |
2018-06-05 |
|
|
1682 |
Pathoanatomy of Traumatic Anterior Instability |
2018-06-05 |
|
|
1683 |
Epidemiology |
2018-06-05 |
|
|
1684 |
Description of the Area and Geological Setting |
2018-06-04 |
|
|
1685 |
Discussion and Results |
2018-06-04 |
|
|
1686 |
Subjects and Method |
2018-05-30 |
|
|
1687 |
Aim of the Study |
2018-05-30 |
|
|
1688 |
Significant of Study |
2018-05-30 |
|
|
1689 |
Clinical Implications |
2018-05-30 |
|
|
1690 |
Conclusion And Future Perspectives |
2018-05-30 |
|
|
1691 |
Target Drug: Solanesol |
2018-05-30 |
|
|
1692 |
Experimental Animal Model For Hd |
2018-05-30 |
|
|
1693 |
Mitochondrial Dysfunction & Hd |
2018-05-30 |
|
|
1694 |
Huntington’s Disease: An Overview |
2018-05-30 |
|
|
1695 |
Implications for Nursing |
2018-05-30 |
|
|
1696 |
Process Delivery |
2018-05-30 |
|
|
1697 |
Developing the Infrastructure |
2018-05-30 |
|
|
1698 |
Results:Conceptions of Mechanism of Action |
2018-05-24 |
|
|
1699 |
Patient Group Directions(PGDS) |
2018-05-24 |
|
|
1700 |
‘Forward Thinking’ and ‘Forward-Doing’ |
2018-05-24 |
|
|
1701 |
Chronic kidney Disease (CKD) |
2018-05-24 |
|
|
1702 |
Miscellaneous Narrations from Some Reported Cases and Discussions |
2018-05-24 |
|
|
1703 |
Results/Literature Review |
2018-05-24 |
|
|
1704 |
Taking Credit for Burnup |
2018-05-10 |
|
|
1705 |
Fresh Fuel |
2018-05-10 |
|
|
1706 |
Analysis |
2018-05-10 |
|
|
1707 |
Contribution statement |
2018-05-04 |
|
|
1708 |
Availability of Data and Materials |
2018-05-04 |
|
|
1709 |
Animal Subjects |
2018-05-04 |
|
|
1710 |
Human Subjects |
2018-05-04 |
|
|
1711 |
Consent and Approval |
2018-05-04 |
|
|
1712 |
Ethics and Consent to Participate |
2018-05-04 |
|
|
1713 |
Future Scope |
2018-05-04 |
|
|
1714 |
Physiological Functions of Selenium |
2018-05-04 |
|
|
1715 |
Literature Review - Selenium |
2018-05-04 |
|
|
1716 |
Discussion & Conclusion |
2018-05-04 |
|
|
1717 |
Poisson process simulation |
2018-05-04 |
|
|
1718 |
Circadian rhythm of cyanobacteria |
2018-05-04 |
|
|
1719 |
Structure of a binary digit of memory in a cell |
2018-05-04 |
|
|
1720 |
Dear Editor |
2018-04-27 |
|
|
1721 |
Laboratory Examinations |
2018-04-19 |
|
|
1722 |
Caution in the use of Bio-Fertilizers |
2018-04-12 |
|
|
1723 |
Limitation of Bio-Fertilizer |
2018-04-12 |
|
|
1724 |
Importance of Bio-Fertilizers |
2018-04-12 |
|
|
1725 |
The Role of Bio-Fertilizers in Enhancing Plant Tolerance to Environmental Stress |
2018-04-12 |
|
|
1726 |
Microorganisms used in Bio-Fertilizer |
2018-04-12 |
|
|
1727 |
Types of Bio-Fertilizers and How they Work |
2018-04-12 |
|
|
1728 |
Differences between Bio-Fertilizer and Organic Fertilizer |
2018-04-12 |
|
|
1729 |
What is Bio-Fertilizer? |
2018-04-12 |
|
|
1730 |
Soil Fertility |
2018-04-12 |
|
|
1731 |
Contribution |
2018-04-12 |
|
|
1732 |
Conflict-of-Interest Disclosure |
2018-04-12 |
|
|
1733 |
Review of Literature |
2018-04-12 |
|
|
1734 |
TTIs and Mass Production |
2018-04-12 |
|
|
1735 |
Intelligent Packaging |
2018-04-12 |
|
|
1736 |
Cold Chains and Storage |
2018-04-12 |
|
|
1737 |
Re-Emerging Disease |
2018-04-12 |
|
|
1738 |
Diagnosis of Avian Influenza A Virus |
2018-04-12 |
|
|
1739 |
Avian Influenza A Virus |
2018-04-12 |
|
|
1740 |
Researcher Exertion |
2018-04-12 |
|
|
1741 |
Scope of the Clinical Microbiology and Infectious Diseases |
2018-04-12 |
|
|
1742 |
Clinical Application |
2018-04-12 |
|
|
1743 |
Declare of Interest Statement |
2018-04-11 |
|
|
1744 |
Future needs for this Area of Research |
2018-04-11 |
|
|
1745 |
Some Medicinal Plants with Anti-Fertility Potential |
2018-04-11 |
|
|
1746 |
POTENTIAL CONFLICTS OF INTEREST |
2018-04-09 |
|
|
1747 |
Skin Typing |
2018-04-09 |
|
|
1748 |
Fractional Thermolysis |
2018-04-09 |
|
|
1749 |
Results and Management |
2018-04-09 |
|
|
1750 |
Financial Disclosures |
2018-04-09 |
|
|
1751 |
Complications |
2018-04-06 |
|
|
1752 |
Funding/Support |
2018-04-06 |
|
|
1753 |
Suggestion for Further Studies |
2018-04-06 |
|
|
1754 |
Human and Animal Rights |
2018-04-06 |
|
|
1755 |
Methods and Patients |
2018-04-06 |
|
|
1756 |
Result |
2018-04-06 |
|
|
1757 |
Ethical considerations |
2018-04-06 |
|
|
1758 |
Implications for Future |
2018-04-03 |
|
|
1759 |
Inability to Cope with Disappointments |
2018-04-03 |
|
|
1760 |
Academic Stress, Anxiety and Depression Among Students |
2018-04-03 |
|
|
1761 |
Parental Pressure |
2018-04-03 |
|
|
1762 |
Reports on Suicide And Parental Pressure Among Children Across India |
2018-04-03 |
|
|
1763 |
At-Risk and Risky Homeless Youth |
2018-04-02 |
|
|
1764 |
Gender and Victimization |
2018-04-02 |
|
|
1765 |
Implications for Practice |
2018-04-02 |
|
|
1766 |
Ancillary Measures Pending Definitive Revascularization |
2018-03-28 |
|
|
1767 |
Anticoagulation |
2018-03-28 |
|
|
1768 |
Initial Management |
2018-03-28 |
|
|
1769 |
Echocardiography |
2018-03-28 |
|
|
1770 |
Definitive Diagnostic Imaging |
2018-03-28 |
|
|
1771 |
Determining the Level of Occlusion |
2018-03-28 |
|
|
1772 |
Classification of ALI |
2018-03-28 |
|
|
1773 |
Clinical Assessment |
2018-03-28 |
|
|
1774 |
Presentation |
2018-03-28 |
|
|
1775 |
Benzodiazepines |
2018-03-27 |
|
|
1776 |
Growth-Differentiation Factor-15 in CV Prediction |
2018-03-27 |
|
|
1777 |
Association between Growth-Differentiation Factor-15 and CV Diseases |
2018-03-27 |
|
|
1778 |
Biological Role and Function of Growth-Differentiation Factor-15 |
2018-03-27 |
|
|
1779 |
Electrochemical Process |
2018-03-22 |
|
|
1780 |
Some Of The Major Treatments Of Oil Produced Water |
2018-03-22 |
|
|
1781 |
Oil and Grease Content (Og) |
2018-03-22 |
|
|
1782 |
Limitations Of The Oil Production Industry And The Wastewater Treatment |
2018-03-22 |
|
|
1783 |
Adaptive Capacity Map |
2018-03-22 |
|
|
1784 |
Human Activities Sensitivity Maps |
2018-03-22 |
|
|
1785 |
Generating the Composite Maps for the Vulnerability Assessment |
2018-03-22 |
|
|
1786 |
Study Region |
2018-03-22 |
|
|
1787 |
Gratitude |
2018-03-20 |
|
|
1788 |
Data Management and Analysis Plan |
2018-03-15 |
|
|
1789 |
Case Summary |
2018-03-15 |
|
|
1790 |
Experimental Therapies directed against Triplet Repeats |
2018-03-03 |
|
|
1791 |
Trinucleotides Repeats Diseases |
2018-03-03 |
|
|
1792 |
Dynamic Mutations |
2018-03-03 |
|
|
1793 |
Treatment and Interventions |
2018-03-02 |
|
|
1794 |
Memory Problems, Suggestibility, and Confabulation |
2018-03-02 |
|
|
1795 |
Adaptive Functioning Considerations |
2018-03-02 |
|
|
1796 |
Executive Functioning Considerations |
2018-03-02 |
|
|
1797 |
Screening and Assessment of FASD |
2018-03-02 |
|
|
1798 |
Distinguishing Primary and Secondary Disabilities of FASD |
2018-03-02 |
|
|
1799 |
Diagnostic Criteria |
2018-03-02 |
|
|
1800 |
Fetal Alcohol Spectrum Disorder (FASD) |
2018-03-02 |
|
|
1801 |
Fund Project |
2018-03-02 |
|
|
1802 |
Contributions |
2018-03-02 |
|
|
1803 |
Declaration |
2018-03-02 |
|
|
1804 |
Medical Observation |
2018-03-02 |
|
|
1805 |
Case Series |
2018-03-01 |
|
|
1806 |
Review |
2018-03-01 |
|
|
1807 |
DISCUSSION |
2018-02-23 |
|
|
1808 |
Numerical Solution of 3D Navier-Stokes Equations |
2018-02-21 |
|
|
1809 |
A Model of Linearized Navier-Stokes Equations |
2018-02-21 |
|
|
1810 |
Recommendation |
2018-02-12 |
|
|
1811 |
The Best Moment to Measure Amh |
2018-02-12 |
|
|
1812 |
Amh Variations Observed During the Natural Cycle |
2018-02-12 |
|
|
1813 |
The Intracycle Variations During Ovarian Stimulation for Ivf-Icsi |
2018-02-12 |
|
|
1814 |
Definitions |
2018-02-03 |
|
|
1815 |
Grant Support |
2018-02-03 |
|
|
1816 |
Patient Consent |
2018-02-03 |
|
|
1817 |
Conflicting Interests |
2018-02-03 |
|
|
1818 |
Details of Contributors |
2018-02-02 |
|
|
1819 |
Cytokine Gene Polymorphisms and Viral Infections |
2018-02-02 |
|
|
1820 |
Biopiles |
2018-02-01 |
|
|
1821 |
Bioventing |
2018-02-01 |
|
|
1822 |
Genetically Engineered Microorganisms (GEMS) |
2018-02-01 |
|
|
1823 |
Types of Bioremediation |
2018-02-01 |
|
|
1824 |
Microorganisms and Pollutants |
2018-02-01 |
|
|
1825 |
Contribution details |
2018-01-30 |
|
|
1826 |
Fragile X Syndrome |
2018-01-17 |
|
|
1827 |
Recommendations for Future Research |
2018-01-17 |
|
|
1828 |
Etiology of Schizophrenia and Parkinson’s |
2018-01-17 |
|
|
1829 |
Discussion and Future Directions |
2018-01-15 |
|
|
1830 |
Improving Phytase Activity by Using Organic Acids |
2018-01-15 |
|
|
1831 |
Phytases and Their Substrate |
2018-01-15 |
|
|
1832 |
Consent |
2018-01-11 |
|
|
1833 |
Ethical Approval |
2018-01-11 |
|
|
1834 |
Research Limitations |
2018-01-11 |
|
|
1835 |
Key Message |
2018-01-11 |
|
|
1836 |
Declarations |
2018-01-10 |
|
|
1837 |
Competing Interest |
2018-01-10 |
|
|
1838 |
Policy Issues |
2018-01-10 |
|
|
1839 |
Toxicity Assays |
2018-01-10 |
|
|
1840 |
Strategies for Developing Animal Models |
2018-01-10 |
|
|
1841 |
Natural Models |
2018-01-10 |
|
|
1842 |
Conflicts of Interest |
2018-01-10 |
|
|
1843 |
Ethical Publication Statement |
2018-01-10 |
|
|
1844 |
Case Study |
2018-01-10 |
|
|
1845 |
Future Directions of Immunohistochemistry |
2018-01-09 |
|
|
1846 |
Application of IHC in Histopathology |
2018-01-09 |
|
|
1847 |
Application of IHC in Histological Research |
2018-01-09 |
|
|
1848 |
Study Area |
2018-01-09 |
|
|
1849 |
Clinical Correlation |
2018-01-09 |
|
|
1850 |
Conclusion and Recommendation |
2018-01-09 |
|
|
1851 |
Plafond fractures, Post-traumatic osteoarthritis and ankle reconctruction |
2018-01-08 |
|
|
1852 |
Clinical outcome of treatment af Tibial Plafond(Pilon) Fractures |
2018-01-08 |
|
|
1853 |
Risk Factors for Post-Traumatic OA |
2018-01-08 |
|
|
1854 |
Pathophysiology Of Osteoarthritis |
2018-01-08 |
|
|
1855 |
Hypothesized Microbial Ecology |
2018-01-08 |
|
|
1856 |
New Geobiological Observations |
2018-01-08 |
|
|
1857 |
Chronostratigraphy |
2018-01-08 |
|
|
1858 |
New Rock Magnetic Measurements |
2018-01-08 |
|
|
1859 |
Reanalysis of the Schwartz et al. (1997) Rock Magnetic Data |
2018-01-08 |
|
|
1860 |
Assessing BBOR Geochemical Conditions |
2018-01-08 |
|
|
1861 |
Blake/Bahama Outer Ridge (BBOR) Sedimentation Processes |
2018-01-08 |
|
|
1862 |
Previous Field Studies |
2018-01-08 |
|
|
1863 |
Results and Conclusion |
2018-01-07 |
|
|
1864 |
Strategies of Minimizing Mortality |
2018-01-07 |
|
|
1865 |
Techniques |
2018-01-07 |
|
|
1866 |
Surgical Revascularization |
2018-01-07 |
|
|
1867 |
Percutaneous Mechanical Thrombectomy (PMT) |
2018-01-07 |
|
|
1868 |
Endovascular Treatment |
2018-01-07 |
|
|
1869 |
Treatment Selection |
2018-01-07 |
|
|
1870 |
Therapeutic Management |
2018-01-07 |
|
|
1871 |
Magnetic Resonance Angiography (MRA) |
2018-01-07 |
|
|
1872 |
CT Angiography |
2018-01-07 |
|
|
1873 |
Conventional Arteriography |
2018-01-07 |
|
|
1874 |
Duplex Ultrasound |
2018-01-07 |
|
|
1875 |
Further Imaging |
2018-01-07 |
|
|
1876 |
Assessment and Classification |
2018-01-07 |
|
|
1877 |
Thrombosis |
2018-01-07 |
|
|
1878 |
Embolism |
2018-01-07 |
|
|
1879 |
Result and Discussion |
2018-01-06 |
|
|
1880 |
Determination of Functional Properties |
2018-01-06 |
|
|
1881 |
Experimental Design and Modelling for Optimization |
2018-01-06 |
|
|
1882 |
Visual Detection |
2018-01-06 |
|
|
1883 |
Food Borne Pathogens |
2018-01-06 |
|
|
1884 |
Regression Analysis |
2018-01-06 |
|
|
1885 |
Correlation and Casuation Analysis |
2018-01-06 |
|
|
1886 |
Gastrointestinal Digestion |
2018-01-06 |
|
|
1887 |
PH Changes |
2018-01-06 |
|
|
1888 |
Drug Development |
2018-01-06 |
|
|
1889 |
Food Safety on Human Health |
2018-01-06 |
|
|
1890 |
Scope |
2018-01-06 |
|
|
1891 |
Non-Coding RNAs |
2018-01-06 |
|
|
1892 |
Radiation and Stress Inducible Genes |
2018-01-06 |
|
|
1893 |
Bacterial and Mitochondial Relationship |
2018-01-06 |
|
|
1894 |
Conclusion and Recommendations |
2018-01-06 |
|
|
1895 |
The Bottom Line for Biotech Entrepreneurship |
2018-01-06 |
|
|
1896 |
Biochemical Entrepreneurship |
2018-01-06 |
|
|
1897 |
Opinion |
2018-01-06 |
|
|
1898 |
Future Work |
2018-01-05 |
|
|
1899 |
Enzymic Synthesis |
2018-01-05 |
|
|
1900 |
Enzyme Immobilization |
2018-01-05 |
|
|
1901 |
Clinical Case Presentation |
2018-01-05 |
|
|
1902 |
Ethical Statement |
2018-01-05 |
|
|
1903 |
Role Of Long Non-Coding RNAs (LncRNAs) in Sci |
2018-01-05 |
|
|
1904 |
Role of miRNA in Sci |
2018-01-05 |
|
|
1905 |
Non-Coding Rna in Spinal Cord Injury |
2018-01-05 |
|
|
1906 |
Role of Stem Cells in Sci |
2018-01-05 |
|
|
1907 |
Conclusion and Outlook |
2018-01-05 |
|
|
1908 |
Environmental Response Mesoporous Silicon Dioxide Drug Delivery System |
2018-01-05 |
|
|
1909 |
Drug Delivery System |
2018-01-05 |
|
|
1910 |
Synthesis of Mesoporous Silica Nanoparticles |
2018-01-05 |
|
|
1911 |
Disclosure |
2018-01-05 |
|
|
1912 |
Data Recollection |
2018-01-05 |
|
|
1913 |
Clinical Implication |
2018-01-05 |
|
|
1914 |
Engineering Application: Hurricane Dynamics and Solution of 3d Navier-Stokes |
2018-01-05 |
|
|
1915 |
Deriving Ermakov-Type Equation for Newtonian Universe with Vortex |
2018-01-04 |
|
|
1916 |
Spiral Galaxy Model |
2018-01-04 |
|
|
1917 |
Solar System Model |
2018-01-04 |
|
|
1918 |
A Few Historical Notes |
2018-01-04 |
|
|
1919 |
Material and Methods |
2018-01-04 |
|
|
1920 |
Introduction- Nerves of the Pelvis |
2018-01-04 |
|
|
1921 |
Summary of Linkers |
2018-01-03 |
|
|
1922 |
Conjugation Chemistry |
2018-01-03 |
|
|
1923 |
Hungarian Experience |
2018-01-03 |
|
|
1924 |
Ethics Committees |
2018-01-03 |
|
|
1925 |
Phases of Drug Development |
2018-01-03 |
|
|
1926 |
Registration Trends of New Drugs |
2018-01-03 |
|
|
1927 |
Implications |
2018-01-03 |
|
|
1928 |
Literature Review |
2018-01-03 |
|
|
1929 |
Rotem platelets |
2018-01-03 |
|
|
1930 |
Rotem |
2018-01-03 |
|
|
1931 |
Teg |
2018-01-03 |
|
|
1932 |
Case Report 2 |
2018-01-03 |
|
|
1933 |
Case Report 1 |
2018-01-03 |
|
|
1934 |
Ethical Consideration |
2018-01-02 |
|
|
1935 |
Grading of the Oocyte Morphology |
2018-01-02 |
|
|
1936 |
Materials |
2018-01-02 |
|
|
1937 |
Pathophysiological Connection Between Tbi and Stroke |
2017-12-27 |
|
|
1938 |
Declaration of Conflicting Interests |
2017-12-27 |
|
|
1939 |
Informed Consent |
2017-12-18 |
|
|
1940 |
Ethics Committee Approval |
2017-12-18 |
|
|
1941 |
Source of Funding |
2017-12-18 |
|
|
1942 |
Trustworties |
2017-12-18 |
|
|
1943 |
Findings Due to Experiences of the Individuals with Stoma |
2017-12-18 |
|
|
1944 |
Material and Method |
2017-12-18 |
|
|
1945 |
Procedures |
2017-12-18 |
|
|
1946 |
Prospect |
2017-12-18 |
|
|
1947 |
Ethical standards |
2017-12-18 |
|
|
1948 |
Short Communication |
2017-12-17 |
|
|
1949 |
Learning Outcome |
2017-12-14 |
|
|
1950 |
Since the Intervention |
2017-12-14 |
|
|
1951 |
Setting up the Project |
2017-12-14 |
|
|
1952 |
The Project |
2017-12-14 |
|
|
1953 |
Literature Survey |
2017-12-14 |
|
|
1954 |
Study Implications |
2017-12-14 |
|
|
1955 |
Discussion and Recommendations |
2017-12-14 |
|
|
1956 |
Observational Findings |
2017-12-14 |
|
|
1957 |
Further Research and Perspectives |
2017-12-13 |
|
|
1958 |
Recommendations For Treatment |
2017-12-05 |
|
|
1959 |
Other Symptoms Not Yet Identified In The Spiritual Or New Age Literature |
2017-12-05 |
|
|
1960 |
Symptoms That Resemble New Age And Spiritual Phenomena |
2017-12-05 |
|
|
1961 |
Symptoms In Schizophrenia |
2017-12-05 |
|
|
1962 |
Measuring Phantom’s Index of Refraction |
2017-12-04 |
|
|
1963 |
Absorption Spectrum of AG Nanoparticles Embedded in gel Phantom |
2017-12-04 |
|
|
1964 |
Optical Properties of Gel Ballistic Phantom |
2017-12-04 |
|
|
1965 |
Theory |
2017-12-04 |
|
|
1966 |
Spectral Measurements |
2017-12-04 |
|
|
1967 |
Experiment |
2017-12-04 |
|
|
1968 |
How India Will Benefit From IT? |
2017-11-30 |
|
|
1969 |
Formulary Manual |
2017-11-30 |
|
|
1970 |
Preparation and Management of Hospi-tal Formulary |
2017-11-30 |
|
|
1971 |
Hospital Formulary System |
2017-11-30 |
|
|
1972 |
External funding source |
2017-11-30 |
|
|
1973 |
Strength of the Study |
2017-11-30 |
|
|
1974 |
Pre-Incubation of Mitochondria in the VLC Fraction |
2017-11-30 |
|
|
1975 |
Mitochondrial Swelling Assay |
2017-11-30 |
|
|
1976 |
Isolation of Rat Liver Mitochondria |
2017-11-30 |
|
|
1977 |
Vacuum Liquid Chromatography Purification Procedure |
2017-11-30 |
|
|
1978 |
Tissue Hormonal Evaluation |
2017-11-30 |
|
|
1979 |
Histopathological Evaluation |
2017-11-30 |
|
|
1980 |
Molecular Evaluation |
2017-11-30 |
|
|
1981 |
Guarantor |
2017-11-30 |
|
|
1982 |
Treatment Schedule |
2017-11-30 |
|
|
1983 |
Objectives |
2017-11-30 |
|
|
1984 |
Observations |
2017-11-27 |
|
|
1985 |
Patients and Observations |
2017-11-25 |
|
|
1986 |
Discussion on Internship |
2017-11-25 |
|
|
1987 |
Letter to the Editor |
2017-11-25 |
|
|
1988 |
Dimensional characteristics of the knee among Asian populations |
2017-11-25 |
|
|
1989 |
According to their occurrence |
2017-11-24 |
|
|
1990 |
Mesiodens |
2017-11-24 |
|
|
1991 |
Theories of Dentigerous cyst formation |
2017-11-24 |
|
|
1992 |
Method |
2017-11-24 |
|
|
1993 |
Authorship |
2017-11-23 |
|
|
1994 |
Author Disclosure Statement |
2017-11-23 |
|
|
1995 |
Clinical Image |
2017-11-16 |
|
|
1996 |
Cardiovascular Treatment and Cancer Risk |
2017-11-16 |
|
|
1997 |
Cardio-Oncology is Crucial |
2017-11-16 |
|
|
1998 |
Detecting Cancers |
2017-11-16 |
|
|
1999 |
Cardiac Effects of Cancer Therapies |
2017-11-16 |
|
|
2000 |
Cardio-Oncology – An Overview |
2017-11-16 |
|
|
2001 |
Methods of Preparation |
2017-11-16 |
|
|
2002 |
Homeostasis |
2017-11-14 |
|
|
2003 |
Concluding Remarks |
2017-11-03 |
|
|
2004 |
Connectomics |
2017-11-03 |
|
|
2005 |
Diffusion Magnetic Resonance Imaging |
2017-11-03 |
|
|
2006 |
Resting-State Functional Brain Imaging |
2017-11-03 |
|
|
2007 |
Functional Brain Imaging |
2017-11-03 |
|
|
2008 |
Commentary |
2017-11-03 |
|
|
2009 |
Data and Materials |
2017-10-17 |
|
|
2010 |
Design of Shape Memory Hybrid |
2017-10-17 |
|
|
2011 |
Experimental |
2017-10-17 |
|
|
2012 |
Description |
2017-10-17 |
|
|
2013 |
Strength and Limitation of the Study |
2017-10-15 |
|
|
2014 |
Source of funding statement |
2017-10-13 |
|
|
2015 |
Authors Contributions |
2017-10-13 |
|
|
2016 |
Rationale |
2017-10-13 |
|
|
2017 |
Letter to Editor |
2017-10-12 |
|
|
2018 |
Estimation of lipid profile levels |
2017-10-12 |
|
|
2019 |
Limitation |
2017-10-12 |
|
|
2020 |
Demographic Information of Poisonous Patients |
2017-10-12 |
|
|
2021 |
Financial Support |
2017-10-12 |
|
|
2022 |
Study limitations |
2017-10-12 |
|
|
2023 |
African and Global Bioethics: Facing the Future |
2017-10-07 |
|
|
2024 |
Bioethics Principles in African Construct |
2017-10-07 |
|
|
2025 |
Method of Collection of Data |
2017-10-07 |
|
|
2026 |
Acceptance of Legislation Against FGM |
2017-10-07 |
|
|
2027 |
Awareness of Campaign Against Female Genital Mutilation |
2017-10-07 |
|
|
2028 |
The steps of fuzzy AHP |
2017-10-07 |
|
|
2029 |
Fuzzy analytic hierarchy process |
2017-10-07 |
|
|
2030 |
Observation |
2017-10-07 |
|
|
2031 |
Histopathological Examination |
2017-10-07 |
|
|
2032 |
Control |
2017-10-07 |
|
|
2033 |
Instruments |
2017-10-06 |
|
|
2034 |
Histopathology Result |
2017-10-06 |
|
|
2035 |
Findings |
2017-10-06 |
|
|
2036 |
Ethical aspects |
2017-10-06 |
|
|
2037 |
Results all OR or RR must be Accompanied by the 95% CI |
2017-10-05 |
|
|
2038 |
Trial Registration Number |
2017-10-05 |
|
|
2039 |
Strengths |
2017-10-05 |
|
|
2040 |
Methods and Analysis |
2017-10-05 |
|
|
2041 |
Complications and Risks Following Surgery |
2017-10-05 |
|
|
2042 |
Complications and Risks Following Surgery |
2017-10-05 |
|
|
2043 |
Indications for Mandibular Third Molar Extraction |
2017-10-05 |
|
|
2044 |
Indications for Mandibular Third Molar Extraction |
2017-10-05 |
|
|
2045 |
Management of Impacted Tooth |
2017-10-05 |
|
|
2046 |
Assessment of Third Molar |
2017-10-05 |
|
|
2047 |
Late Crowding in Lower Incisors |
2017-10-05 |
|
|
2048 |
Case History |
2017-10-05 |
|
|
2049 |
Pathological Changes Associated with Impacted Third Molars |
2017-10-05 |
|
|
2050 |
Classification |
2017-10-05 |
|
|
2051 |
Causes of Impacted Teeth |
2017-10-05 |
|
|
2052 |
Source of Support |
2017-10-05 |
|
|
2053 |
Surgical Procedure |
2017-10-05 |
|
|
2054 |
Challenges |
2017-10-05 |
|
|
2055 |
Technical Note |
2017-10-05 |
|
|
2056 |
Administrative skills |
2017-10-05 |
|
|
2057 |
Skill acquisition |
2017-10-05 |
|
|
2058 |
Study design |
2017-10-05 |
|
|
2059 |
Study population |
2017-10-05 |
|
|
2060 |
Detection of carbapenemase production |
2017-10-05 |
|
|
2061 |
Conclusion/Recommendation |
2017-10-05 |
|
|
2062 |
Argument Based on Socio-Cultural Values |
2017-10-05 |
|
|
2063 |
Design |
2017-10-05 |
|
|
2064 |
Strengths and Limitations |
2017-10-05 |
|
|
2065 |
Imaging and Management |
2017-10-05 |
|
|
2066 |
Conclusions and Recommendation |
2017-10-05 |
|
|
2067 |
Limitation to the Study |
2017-10-05 |
|
|
2068 |
Methods for the Case Series |
2017-10-05 |
|
|
2069 |
Artemisinins Toxicity |
2017-10-05 |
|
|
2070 |
Resistance to Artemisinins |
2017-10-05 |
|
|
2071 |
Artemisinins in Combination Chemotherapy for Cancer |
2017-10-05 |
|
|
2072 |
Artemisinins |
2017-10-05 |
|
|
2073 |
Methods of Literature Search |
2017-10-05 |
|
|
2074 |
Observations and Results |
2017-10-05 |
|
|
2075 |
Clinical Presentation |
2017-10-05 |
|
|
2076 |
Method of Registry Compilation |
2017-10-04 |
|
|
2077 |
Results and Statistical Analysis |
2017-10-04 |
|
|
2078 |
Statistical Method |
2017-10-04 |
|
|
2079 |
Procedure |
2017-10-04 |
|
|
2080 |
Conclusion and Final Considerations |
2017-10-04 |
|
|
2081 |
Objective |
2017-10-04 |
|
|
2082 |
Oral Health Care Reforms in Developed Countries |
2017-10-04 |
|
|
2083 |
Dental Insurance Policy |
2017-10-04 |
|
|
2084 |
Mobile and Portable Dental Services |
2017-10-04 |
|
|
2085 |
Public-private Partnership |
2017-10-04 |
|
|
2086 |
Street Dentistry: Tackling Quackery |
2017-10-04 |
|
|
2087 |
Strategy to Improve Oral Health of Children |
2017-10-04 |
|
|
2088 |
Improving Geriatric Oral Health |
2017-10-04 |
|
|
2089 |
Loss of Working Hours |
2017-10-04 |
|
|
2090 |
Oral Health Care Expenditure |
2017-10-04 |
|
|
2091 |
Barriers in Oral Health Promotion |
2017-10-04 |
|
|
2092 |
Oral Health Burden in India |
2017-10-04 |
|
|
2093 |
Case Reports |
2017-10-04 |
|
|
2094 |
What Can Physicians Do? The Public Health Approach |
2017-10-04 |
|
|
2095 |
Response by the Nigerian Government |
2017-10-04 |
|
|
2096 |
Why Does Road Traffic Accidents Deserve the Government’s Time, Energy and Focus? |
2017-10-04 |
|
|
2097 |
Competing Interests |
2017-10-04 |
|
|
2098 |
Image Article |
2017-09-25 |
|
|
2099 |
Corrections Made |
2017-09-25 |
|
|
2100 |
Article Corrected |
2017-09-25 |
|
|
2101 |
Financial support and sponsorship |
2017-09-22 |
|
|
2102 |
Method of Literature Search |
2017-09-22 |
|
|
2103 |
Do not Forget to Negotiate |
2017-09-22 |
|
|
2104 |
Involve the Team in Budget Planning |
2017-09-22 |
|
|
2105 |
Beware Relying too Much on the Previous Cycle’s Activity and Budget |
2017-09-22 |
|
|
2106 |
Consider What Your Budget Cycle Should be |
2017-09-22 |
|
|
2107 |
Evaluate the Outcomes, Learn from Them,and Start Planning Again |
2017-09-22 |
|
|
2108 |
Monitor Adherence to the Planned Budget |
2017-09-22 |
|
|
2109 |
Communicate the Budget Plan to the Team |
2017-09-22 |
|
|
2110 |
Get Involved in Budget Planning |
2017-09-22 |
|
|
2111 |
Think About Your Department’s Goals and Strategy |
2017-09-22 |
|
|
2112 |
Addendum |
2017-09-21 |
|
|
2113 |
Clinical Significance |
2017-09-21 |
|
|
2114 |
CONCLUSION |
2017-09-21 |
|
|
2115 |
Case |
2017-09-17 |
|
|
2116 |
The Empirical Study and Results |
2017-09-17 |
|
|
2117 |
Background and A Brief Overview of The Study |
2017-09-17 |
|
|
2118 |
Cardiovascular Safety |
2017-09-14 |
|
|
2119 |
Phase III Studies |
2017-09-14 |
|
|
2120 |
Efficacy in Patients with ED |
2017-09-14 |
|
|
2121 |
Drug Interactions |
2017-09-14 |
|
|
2122 |
Clinical Pharmacokinetics and Metabolism |
2017-09-14 |
|
|
2123 |
Implications for Future Studies |
2017-09-14 |
|
|
2124 |
Risk factors for GenitaL Chlamydia |
2017-09-14 |
|
|
2125 |
Occurrence of Genital Chlamydia |
2017-09-14 |
|
|
2126 |
Surgery |
2017-09-14 |
|
|
2127 |
Other Techniques |
2017-09-14 |
|
|
2128 |
Nerve Stimulation |
2017-09-14 |
|
|
2129 |
Bladder Hydrodistension |
2017-09-14 |
|
|
2130 |
Intravesical Agents |
2017-09-14 |
|
|
2131 |
Oral Medication |
2017-09-14 |
|
|
2132 |
Lifestyle |
2017-09-14 |
|
|
2133 |
Chronic Pelvic Pain Syndrome: Similarity To IC |
2017-09-14 |
|
|
2134 |
Diagnostic Tools |
2017-09-14 |
|
|
2135 |
Etiology and Pathogenesis |
2017-09-14 |
|
|
2136 |
Epidemiology and History |
2017-09-14 |
|
|
2137 |
The Adolescent |
2017-09-14 |
|
|
2138 |
Puberty |
2017-09-14 |
|
|
2139 |
Common Gynecological Disorders of the Prepubertal Child |
2017-09-14 |
|
|
2140 |
Examination of the Prepubertal Child |
2017-09-14 |
|
|
2141 |
Treatment Strategies for Professional Sexual Misconduct |
2017-09-14 |
|
|
2142 |
Key Points |
2017-09-13 |
|
|
2143 |
Treatment and follow-up of Neonatal Hsv Infection |
2017-09-13 |
|
|
2144 |
Laboratory Diagnosis |
2017-09-13 |
|
|
2145 |
Management of the Exposed Asymptomatic Newborn |
2017-09-13 |
|
|
2146 |
Prevention of Neonatal Hsv Infection |
2017-09-13 |
|
|
2147 |
Features of Neonatal Hsv Infections |
2017-09-13 |
|
|
2148 |
Bibliography |
2017-09-13 |
|
|
2149 |
Prevention and Treatment of Male Osteoporosis |
2017-09-13 |
|
|
2150 |
Bone Mineral Density, and Risk Factors for Osteoporosis and Fracture |
2017-09-13 |
|
|
2151 |
Etiology and Pathogenesis |
2017-09-13 |
|
|
2152 |
Epidemiology of Osteoporosis and Fractures in men |
2017-09-13 |
|
|
2153 |
Significance to Clinicians |
2017-09-13 |
|
|
2154 |
Congenital Anomalies in IVF and ICSI |
2017-09-13 |
|
|
2155 |
Chromosomal Abnormalities After IVF and ICSI |
2017-09-13 |
|
|
2156 |
Spontaneous Abortion Rate with IVF and ICSI |
2017-09-13 |
|
|
2157 |
Transmission of Existing Genetic Abnormalities Through Assisted Reproduction |
2017-09-13 |
|
|
2158 |
What are These Conditions? |
2017-09-13 |
|
|
2159 |
Are They Really the Same Condition? |
2017-09-13 |
|
|
2160 |
Complications and Limitations of Art |
2017-09-13 |
|
|
2161 |
Results of Assisted Reproduction |
2017-09-13 |
|
|
2162 |
New Developments in Art |
2017-09-13 |
|
|
2163 |
Oocyte Donation |
2017-09-13 |
|
|
2164 |
Cryopreservation in Art |
2017-09-13 |
|
|
2165 |
Prostate Biopsy |
2017-09-13 |
|
|
2166 |
Serum Markers and Digital Rectal Examination |
2017-09-13 |
|
|
2167 |
Prostatic Carcinogenesis and Hormones |
2017-09-13 |
|
|
2168 |
Results of Treatment |
2017-09-13 |
|
|
2169 |
Therapeutic Options |
2017-09-13 |
|
|
2170 |
Androgen Deficiency in the aging male and Sex: Clicnical Picture |
2017-09-13 |
|
|
2171 |
Androgen Deficiency in the aging male and Sex: Clicnical Picture |
2017-09-13 |
|
|
2172 |
Vasectomy Reversal |
2017-09-13 |
|
|
2173 |
Vasectomy |
2017-09-13 |
|
|
2174 |
Empirical Therapy |
2017-09-13 |
|
|
2175 |
Specific Pharmacological Therapy |
2017-09-13 |
|
|
2176 |
Specific surgical Therapy |
2017-09-13 |
|
|
2177 |
Management |
2017-09-13 |
|
|
2178 |
Laboratory Tests |
2017-09-13 |
|
|
2179 |
Testosterone is Not Just Sexual |
2017-09-13 |
|
|
2180 |
Evaluation |
2017-09-13 |
|
|
2181 |
Case Presentations |
2017-09-13 |
|
|
2182 |
Length of Treatment |
2017-09-13 |
|
|
2183 |
Obstructive Oligospermia |
2017-09-13 |
|
|
2184 |
Depression and Andropause |
2017-09-13 |
|
|
2185 |
Chemotherapy, Radiation and Gonadotoxins |
2017-09-13 |
|
|
2186 |
Fever and Oligoasthenospermia |
2017-09-13 |
|
|
2187 |
Antisperm Antibodies |
2017-09-13 |
|
|
2188 |
Sexual Dysfunction in Depression |
2017-09-13 |
|
|
2189 |
Pyospermia |
2017-09-13 |
|
|
2190 |
Major Depression |
2017-09-13 |
|
|
2191 |
Genetic Disorders |
2017-09-13 |
|
|
2192 |
Cryptorchidism |
2017-09-13 |
|
|
2193 |
Effect of Decreased Testosterone Levels |
2017-09-13 |
|
|
2194 |
Varicocele |
2017-09-13 |
|
|
2195 |
Testosterone Physiology |
2017-09-13 |
|
|
2196 |
Endocrinological Abnormalities |
2017-09-13 |
|
|
2197 |
Prevention and Treatment |
2017-09-13 |
|
|
2198 |
Mechanisms of SCD |
2017-09-13 |
|
|
2199 |
CAD and Cardiomyopathies |
2017-09-13 |
|
|
2200 |
Patient Preference |
2017-09-13 |
|
|
2201 |
Efficacy |
2017-09-13 |
|
|
2202 |
Outcome Measures |
2017-09-13 |
|
|
2203 |
Pharmacology of Tadalafil |
2017-09-13 |
|
|
2204 |
Safety |
2017-09-13 |
|
|
2205 |
Is Reliability Important |
2017-09-13 |
|
|
2206 |
Vardenafil Works Rapidly |
2017-09-13 |
|
|
2207 |
Therapeutic Efficacy |
2017-09-13 |
|
|
2208 |
Experimental Setup |
2017-09-13 |
|
|
2209 |
Nuclear Licensing Regimes |
2017-09-13 |
|
|
2210 |
Independence of the Regulatory Authority |
2017-09-13 |
|
|
2211 |
Target Organs |
2017-09-12 |
|
|
2212 |
Testosterone |
2017-09-12 |
|
|
2213 |
Testes |
2017-09-12 |
|
|
2214 |
Hypothalamus and Pituitary Function |
2017-09-12 |
|
|
2215 |
Testosterone and Stress – The Cortex |
2017-09-12 |
|
|
2216 |
The High Testosterone Male |
2017-09-12 |
|
|
2217 |
Androgen Profile |
2017-09-12 |
|
|
2218 |
Luteinizing Hormone |
2017-09-12 |
|
|
2219 |
Prolactin |
2017-09-12 |
|
|
2220 |
Insulinemia |
2017-09-12 |
|
|
2221 |
Thyroid Profile |
2017-09-12 |
|
|
2222 |
Basic Biochemical Profile |
2017-09-12 |
|
|
2223 |
Symptoms of Andropause |
2017-09-12 |
|
|
2224 |
Clinical Diagnosis of Andropause |
2017-09-12 |
|
|
2225 |
Screening for Andropause |
2017-09-12 |
|
|
2226 |
Definition |
2017-09-12 |
|
|
2227 |
Varicocelectomy |
2017-09-12 |
|
|
2228 |
Diagnosis |
2017-09-12 |
|
|
2229 |
Testicular atrophy |
2017-09-12 |
|
|
2230 |
Pathophysiology |
2017-09-12 |
|
|
2231 |
Mechanisms |
2017-09-12 |
|
|
2232 |
Etiology |
2017-09-12 |
|
|
2233 |
Incidence |
2017-09-12 |
|
|
2234 |
Assisted Reproduction for Obstructive Azoospermia |
2017-09-11 |
|
|
2235 |
Evaluation for Obstructive Azoospermia |
2017-09-11 |
|
|
2236 |
Obstructive Azoospermia |
2017-09-11 |
|
|
2237 |
Assisted Reproduction for Nonobstructive Azoospermia |
2017-09-11 |
|
|
2238 |
Treatments for Nonobstructive Azoospermia |
2017-09-11 |
|
|
2239 |
Nonobstructive Azoospermia |
2017-09-11 |
|
|
2240 |
Investigations |
2017-09-11 |
|
|
2241 |
Specialized Tests |
2017-09-11 |
|
|
2242 |
Ultrasound Evaluation |
2017-09-11 |
|
|
2243 |
Hormonal Studies |
2017-09-11 |
|
|
2244 |
Basic Tests |
2017-09-11 |
|
|
2245 |
Physical Examinations |
2017-09-11 |
|
|
2246 |
Clinical History |
2017-09-11 |
|
|
2247 |
Clinical Evaluation – Anotomical and Phyiological Considerations |
2017-09-11 |
|
|
2248 |
Apomorphine: A centrally Acting Oral Ed therapy |
2017-09-11 |
|
|
2249 |
New Pde-5 Inhibitors |
2017-09-11 |
|
|
2250 |
Treatment |
2017-09-11 |
|
|
2251 |
Prevention |
2017-09-11 |
|
|
2252 |
Clinical Investigations |
2017-09-11 |
|
|
2253 |
Neurovascular anatomy and Vulnerability |
2017-09-11 |
|
|
2254 |
surveys |
2017-09-11 |
|
|
2255 |
Case Studies |
2017-09-11 |
|
|
2256 |
Managing Ejaculatory and Orgasmic Disorders |
2017-09-11 |
|
|
2257 |
Clinical Definitions of Ejaculatory and Orgasmic Concerns |
2017-09-11 |
|
|
2258 |
Orgasm and Ejaculation:What is the difference? |
2017-09-11 |
|
|
2259 |
Recommendations |
2017-09-11 |
|
|
2260 |
Making the Diagnosis |
2017-09-11 |
|
|
2261 |
The Step-Wise Approach to the Patient |
2017-09-11 |
|
|
2262 |
Global Management Objectives |
2017-09-11 |
|
|
2263 |
Summary Concepts |
2017-09-11 |
|
|
2264 |
Sexuality Education For The Adolescent |
2017-09-11 |
|
|
2265 |
Sexuality Education For The Child In Early Puberty |
2017-09-11 |
|
|
2266 |
Sexuality Development In Prepubertal Children |
2017-09-11 |
|
|
2267 |
Data and Methods |
2017-09-11 |
|
|
2268 |
Future Challenges |
2017-09-11 |
|
|
2269 |
Genital Chlamydial Infection |
2017-09-11 |
|
|
2270 |
Syphilis |
2017-09-11 |
|
|
2271 |
Gonorrhea |
2017-09-11 |
|
|
2272 |
Hormonal Regimen After Srs |
2017-09-11 |
|
|
2273 |
Outcome of Low Dose Estrogen Administration, Testosterone Suppression and Antagonism |
2017-09-11 |
|
|
2274 |
Individualization of Estrogen Administration |
2017-09-11 |
|
|
2275 |
Author’s Contribution |
2017-09-11 |
|
|
2276 |
Additional Potential Risks of Estrogen Administration |
2017-09-11 |
|
|
2277 |
Sexual Behaviour And Club Drugs |
2017-09-11 |
|
|
2278 |
Authors’ Contribution |
2017-09-11 |
|
|
2279 |
Ketamine |
2017-09-11 |
|
|
2280 |
Estrogen Administration and Cardiovascular Risk |
2017-09-11 |
|
|
2281 |
Methamphetamine |
2017-09-11 |
|
|
2282 |
Estrogen Administration and Cardiovascular Protection |
2017-09-11 |
|
|
2283 |
Feminization with Physiological Estrogen |
2017-09-11 |
|
|
2284 |
GHB |
2017-09-11 |
|
|
2285 |
LH Suppression |
2017-09-11 |
|
|
2286 |
MDMA |
2017-09-11 |
|
|
2287 |
Model Hormonal Regimen |
2017-09-11 |
|
|
2288 |
Drugs Used in Hormonal Treatment for Male to Female Gid |
2017-09-11 |
|
|
2289 |
Nursing Perspectives on Sexual Health |
2017-09-11 |
|
|
2290 |
FADS |
2017-09-11 |
|
|
2291 |
Treatment Strategies |
2017-09-11 |
|
|
2292 |
Diagnostic Approach |
2017-09-11 |
|
|
2293 |
The Four Causes Of Female Sexual Dysfunction |
2017-09-11 |
|
|
2294 |
Anatomy And Physiology Of The Female Sexual Response |
2017-09-11 |
|
|
2295 |
Prevalence |
2017-09-11 |
|
|
2296 |
Definition Of Female Sexual Dysfunction |
2017-09-11 |
|
|
2297 |
Research Design and Methods |
2017-09-11 |
|
|
2298 |
Review of Previous Studies |
2017-09-11 |
|
|
2299 |
The Application of Acupuncture Research in Metabo Nomics |
2017-09-11 |
|
|
2300 |
Metabo Nomics Research Methods |
2017-09-11 |
|
|
2301 |
Definition of Metabo Nomics |
2017-09-11 |
|
|
2302 |
Future Perspectives |
2017-09-11 |
|
|
2303 |
Tissue Engineering using 3D Bioprinting |
2017-09-11 |
|
|
2304 |
Material Factors |
2017-09-11 |
|
|
2305 |
3D Bioprinting |
2017-09-11 |
|
|
2306 |
Limitations of Therapeutic Stem Cell Use |
2017-09-11 |
|
|
2307 |
Stem Cells |
2017-09-11 |
|
|
2308 |
Statement of Competing Interests |
2017-09-11 |
|
|
2309 |
Limitations of our study and future research |
2017-09-11 |
|
|
2310 |
Existing Problems and Prospects in Research of Metabolomics in TCM |
2017-09-11 |
|
|
2311 |
Metabonomic Research on Mechanisms of Single Chinese Medicine |
2017-09-11 |
|
|
2312 |
Metabonomic Study of the Pharmacodynamic Material basis of Single Herbs |
2017-09-11 |
|
|
2313 |
Research Content and Process of Metabolomics |
2017-09-11 |
|
|
2314 |
Foundation Support |
2017-09-11 |
|
|
2315 |
Possible Mechanisms |
2017-09-10 |
|
|
2316 |
Cardiac Tolerance to Hypoxia in Poikilotherms |
2017-09-10 |
|
|
2317 |
Determinants of the Development of Compact Musculature with Vascular Supply |
2017-09-10 |
|
|
2318 |
Comparative Aspects of the Myocardial Structure/blood Supply Relationship |
2017-09-10 |
|
|
2319 |
Clinical Trials Demonstrating the Cardioprotective Effects of ALA |
2017-09-10 |
|
|
2320 |
Animal Research Demonstrating the Cardioprotective Effects of ALA |
2017-09-10 |
|
|
2321 |
Absorption Characteristics and Bioavailability of ALA |
2017-09-10 |
|
|
2322 |
Omega-3 Fatty Acids and CVD |
2017-09-10 |
|
|
2323 |
Omega-3 Fatty Acid Structure and Metabolism |
2017-09-10 |
|
|
2324 |
The Role of Fibre and Omega-3 Fatty Acids |
2017-09-10 |
|
|
2325 |
Functional Foods for the Prevention and Treatment of Cardiovascular Disease |
2017-09-10 |
|
|
2326 |
Multidisciplinary Support |
2017-09-10 |
|
|
2327 |
Use of Topical Adjuncts for Hemostasis |
2017-09-10 |
|
|
2328 |
Alteration of Cooling/Neuroprotective Strategies to Optimize Effects on the Coagulation Cascade |
2017-09-10 |
|
|
2329 |
Miniaturized Cpb |
2017-09-10 |
|
|
2330 |
Modification in Cpb Circuit and Prime Composition |
2017-09-10 |
|
|
2331 |
Autologous Transfusion |
2017-09-10 |
|
|
2332 |
Desmopressin |
2017-09-10 |
|
|
2333 |
Synthetic Lysine Analogues |
2017-09-10 |
|
|
2334 |
Fibrinogen |
2017-09-10 |
|
|
2335 |
Restrictive Transfusion Therapy |
2017-09-10 |
|
|
2336 |
Pharmacotherapy to Increase Blood Volume and Reduce Blood Loss |
2017-09-10 |
|
|
2337 |
Sources Of Funding |
2017-09-10 |
|
|
2338 |
Gene Delivery systems |
2017-09-09 |
|
|
2339 |
Therapeutic Gene targets |
2017-09-09 |
|
|
2340 |
Evolution of antirestenosis therapy |
2017-09-09 |
|
|
2341 |
Angiographic Follow-Up |
2017-09-09 |
|
|
2342 |
Two-Stent Versus Conventional Single-Stent Strategy |
2017-09-09 |
|
|
2343 |
Assessing The Severity Of LMCA Obstruction |
2017-09-09 |
|
|
2344 |
Risk Stratification |
2017-09-09 |
|
|
2345 |
Revascularization Of LMCA Stenosis |
2017-09-09 |
|
|
2346 |
Anatomy Of the LMCA |
2017-09-09 |
|
|
2347 |
Funding Sources |
2017-09-09 |
|
|
2348 |
Clinical aspects of ECM remodelling |
2017-09-09 |
|
|
2349 |
Changes in ECM composition as a consequence of myocardial ischemia |
2017-09-09 |
|
|
2350 |
The inflammatory response and changes in the ECM |
2017-09-09 |
|
|
2351 |
Myofibroblast activity and ECM changes during the course of CHF |
2017-09-09 |
|
|
2352 |
Composition and function of the ecm and the role of myofibroblasts in the myocardium |
2017-09-09 |
|
|
2353 |
Pathophysiology of myocardial remodelling in CHF |
2017-09-09 |
|
|
2354 |
Summary and Conclusions |
2017-09-09 |
|
|
2355 |
Herbal Therapies for ED |
2017-09-09 |
|
|
2356 |
Contraindications of PDE-5 inhibitors and adverse reactions |
2017-09-09 |
|
|
2357 |
Current Therapy for ED |
2017-09-09 |
|
|
2358 |
Pathophysiology of ED and Priapism |
2017-09-09 |
|
|
2359 |
Evidence-based Inotrope use in Different Cardiovascular scenarios |
2017-09-09 |
|
|
2360 |
Adverse Reactions to inotropres anD Vasopressors |
2017-09-09 |
|
|
2361 |
New Inotropic Agents and future Directions |
2017-09-09 |
|
|
2362 |
Calcium-sensitizinG agents |
2017-09-08 |
|
|
2363 |
Vasopressin |
2017-09-08 |
|
|
2364 |
Phosphodiesterase Inhibitors |
2017-09-08 |
|
|
2365 |
Catecholamines |
2017-09-08 |
|
|
2366 |
Contributorship |
2017-09-08 |
|
|
2367 |
Highlights |
2017-09-08 |
|
|
2368 |
Currently Used Techniques for the Evaluat ion of Heart Involvement in MD ECG |
2017-09-08 |
|
|
2369 |
The Future of Research on Nucleocytoplasmic Trafficking |
2017-09-08 |
|
|
2370 |
Ran and Nuclear Transport |
2017-09-08 |
|
|
2371 |
Ran and Nuclear Transport |
2017-09-08 |
|
|
2372 |
Nuclear Transport Receptors |
2017-09-08 |
|
|
2373 |
Nuclear Transport Signal Sequences |
2017-09-08 |
|
|
2374 |
Models of Transport |
2017-09-08 |
|
|
2375 |
The NPC |
2017-09-08 |
|
|
2376 |
Nucleocytoplasmic Trafficking |
2017-09-08 |
|
|
2377 |
Funding |
2017-09-07 |
|
|
2378 |
Percuta Neous Lv Support Devices |
2017-09-07 |
|
|
2379 |
Intra-Aortic Balloon Pump |
2017-09-07 |
|
|
2380 |
Left Ventricle Unloading |
2017-09-07 |
|
|
2381 |
Left Ventricular Overload During Va-Ecmo Therapy |
2017-09-07 |
|
|
2382 |
Clinical Indications for Va-Ecmo |
2017-09-07 |
|
|
2383 |
Methodology |
2017-09-07 |
|
|
2384 |
Conclusion and Limitations |
2017-09-07 |
|
|
2385 |
Patellar Sleeve Injuries |
2017-09-07 |
|
|
2386 |
Apophyseal Avulsions |
2017-09-07 |
|
|
2387 |
Transitional Ankle Injuries |
2017-09-07 |
|
|
2388 |
Tibia Tubercle Fractures |
2017-09-07 |
|
|
2389 |
Pre-Fusion |
2017-09-07 |
|
|
2390 |
Medial Epicondyle Fractures |
2017-09-07 |
|
|
2391 |
Ossification |
2017-09-07 |
|
|
2392 |
Femoral Physeal Separation |
2017-09-07 |
|
|
2393 |
Distal Humeral Physeal Separation |
2017-09-07 |
|
|
2394 |
Pre-Ossification |
2017-09-07 |
|
|
2395 |
General Considerations |
2017-09-07 |
|
|
2396 |
Compliance with Ethical Standards |
2017-09-07 |
|
|
2397 |
Patients and Methods |
2017-09-07 |
|
|
2398 |
Applying the Algorithm |
2017-09-07 |
|
|
2399 |
Experimental Procedure |
2017-09-06 |
|
|
2400 |
Background |
2017-09-06 |
|
|
2401 |
Results and Discussion |
2017-09-06 |
|
|
2402 |
Animations |
2017-09-06 |
|
|
2403 |
Operative Technique |
2017-09-06 |
|
|
2404 |
New Trends in “Treatment” |
2017-09-06 |
|
|
2405 |
New Trends in “Diagnosis” |
2017-09-06 |
|
|
2406 |
Cardiac Injury Leads to Fibrosis |
2017-09-06 |
|
|
2407 |
Oxidative Stress and Neurohormonal Activation Cause Ca2+ Transport Dysfunction |
2017-09-06 |
|
|
2408 |
ROS and Cardiac Hypertrophy Signalling |
2017-09-06 |
|
|
2409 |
Oxidative Stress as a Major Event in Cardiac Remodelling |
2017-09-06 |
|
|
2410 |
Summary |
2017-09-06 |
|
|
2411 |
Reversing Subcellular Remodelling |
2017-09-06 |
|
|
2412 |
Deiodinase 3 and Intracellular Thyroid Hormone Signalling |
2017-09-06 |
|
|
2413 |
Subcellular Remodelling |
2017-09-06 |
|
|
2414 |
Possible Etiology |
2017-09-06 |
|
|
2415 |
Discussion and Conclusion |
2017-09-06 |
|
|
2416 |
Editorial |
2017-09-06 |
|
|
2417 |
Conflict of Interest Statement |
2017-09-06 |
|
|
2418 |
Acknowledgements |
2017-09-06 |
|
|
2419 |
Case 3 |
2017-09-05 |
|
|
2420 |
Case 2 |
2017-09-05 |
|
|
2421 |
Case 1 |
2017-09-05 |
|
|
2422 |
Case Presentation |
2017-09-05 |
|
|
2423 |
MRI Processing |
2017-09-05 |
|
|
2424 |
Skeletal Muscle Diseases Commonly Associated with Cardiac Involvement |
2017-09-01 |
|
|
2425 |
Declaration of Conflict of Interest |
2017-08-31 |
|
|
2426 |
Hepatitis E virus Transmission |
2017-08-31 |
|
|
2427 |
Development |
2017-08-31 |
|
|
2428 |
Evidence acquisition |
2017-08-31 |
|
|
2429 |
Aims and Objectives |
2017-08-31 |
|
|
2430 |
Data analysis |
2017-08-30 |
|
|
2431 |
Subjects and Methods |
2017-08-30 |
|
|
2432 |
Author Contribution |
2017-08-30 |
|
|
2433 |
Aim |
2017-08-30 |
|
|
2434 |
Methods |
2017-08-29 |
|
|
2435 |
Limitations of the Study |
2017-08-17 |
|
|
2436 |
Statistical Analysis |
2017-08-17 |
|
|
2437 |
Ethical Disclosures |
2017-08-16 |
|
|
2438 |
Case Presentation |
2017-08-16 |
|
|
2439 |
No heading |
2017-08-16 |
|
|
2440 |
Abbreviations |
2017-08-16 |
|
|
2441 |
Conflict of Interest |
2017-08-16 |
|
|
2442 |
Limitations |
2017-08-16 |
|
|
2443 |
Case Report |
2017-08-16 |
|
|
2444 |
Disclosures |
2017-08-12 |
|
|
2445 |
Funding Source |
2017-08-12 |
|
|
2446 |
Acknowledgement |
2017-08-12 |
|
|
2447 |
Conclusion |
2017-08-12 |
|
|
2448 |
Keywords |
2017-08-12 |
|
|
2449 |
REFERENCES |
2017-08-10 |
|
|
2450 |
Discussion |
2017-08-10 |
|
|
2451 |
Results |
2017-08-10 |
|
|
2452 |
Materials and Methods |
2017-08-10 |
|
|
2453 |
Introduction |
2017-08-10 |
|
|
2454 |
Abstract |
2017-08-10 |
|
|